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II.  
ABSTRACT  
Medulloblastoma is the most common malignant childhood brain tumour, and the most 
significant cause of childhood cancer-related mortality. Recently four core molecular 
medulloblastoma sub-groups have been identified, with distinct pathogenesis and responses 
to therapies. Current therapies, do not account for this molecular variation, and many patients 
may receive inappropriate treatment. To address this, targeted therapies for each molecular 
sub-group would be ideal. Unfortunately, for the more aggressive Group 3 and Group 4 sub-
groups, the underlying mechanisms of pathogenesis remain poorly understood. The current 
challenge is to identify the key tumour suppressors or oncogenes involved in Group 3 and 
Group 4 pathogenesis, which may ultimately lead to the development of new therapeutic 
targets. 
 
Transcriptional profiling studies of medulloblastoma have identified numerous genes 
commonly affected in other cancers, which may also contribute to medulloblastoma 
pathogenesis.  One potential candidate is Dachshund Homolog 1 (DACH1), which has up-
regulated expression across all medulloblastoma sub-groups, relative to normal cerebellum, 
consistent with a potential oncogenic role. This up-regulation is most significant in the Group 
4 tumours and is consistent with recent methylation profiling analyses, correlating increased 
DACH1 expression with gene hypomethylation. This combined evidence suggests that 
DACH1 may be a medulloblastoma oncogene. Oncogenic over-expression of DACH1 has 
been demonstrated in both ovarian and colorectal cancers, and is associated with cancer 
progression and invasiveness, but has not previously been linked to medulloblastoma 
pathogenesis. Additionally the mechanisms associated with over-expression of DACH1 have 
not been explored in any cancers; however epigenetic modulation is likely, as DACH1 
mutations are relatively rare in most cancer types, and DACH1 mutations in medulloblastoma 
have not been identified.  
 
Deregulated expression of numerous microRNAs has been identified in various cancers, 
including medulloblastoma, demonstrating the role of microRNAs in cancer initiation and 
progression. MicroRNAs provide a potential epigenetic mechanism for regulation of 
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DACH1. Analysis of the DACH1 3’UTR using TargetScan revealed a potential binding sites 
for nine individual/clusters of miRNAs (Figure 10). One putative miRNA is miR-200b, 
belonging to the highly conserved microRNA-200 family (miR-200). miR-200 is frequently 
down-regulated in metastatic cancers, raising the possibility that the miR-200 family may 
play a role in the pathogenesis of metastatic Group 4 medulloblastoma.  
 
There is an apparent association between high levels of DACH1 expression and low level of 
miR-200b, and in silico analysis using TargetScan identified a putative binding site for miR-
200b within the DACH1 3’-UTR at nucleotides 971-978. Previous evidence supports the role 
of both DACH1 and miR-200b in metastatic progression; however an association between the 
two has not previously been described. Here we propose that deregulated DACH1 was 
associated with loss of regulation by miR-200b, and demonstrated an inverse correlation 
between DACH1 and mir-200b expression in representative medulloblastoma cell lines, 
which was further assessed.  
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1.0 MEDULLOBLASTOMA 
Medulloblastoma is the most common malignant brain tumour in children, and occurs in the 
cerebellum. The clinical heterogeneity of these tumours has now been linked to variations at 
a molecular level, distinguishing at least four distinct sub-groups. These core sub-groups 
include the Sonic Hedgehog tumours (SHH), Wingless tumours (WNT), Group 3 tumours, 
and Group 4 tumours.  For SHH and WNT tumours, aberrant overexpression of the respective 
pathways is responsible for driving tumourigenesis. However, the pathogenesis of both 
Group 3 and Group 4 tumours is more complex, most likely involving interactions between 
different signalling and genetic factors. In Group 3, MYC amplification is the most striking 
abnormality, and in Group 4, recurrent mutations affecting epigenetic regulator genes are 
prominent. 
 
Given the molecular and clinical heterogeneity of medulloblastoma, it would be ideal to treat 
patients according to molecular sub-group, however current treatment regimens are 
determined using a risk stratification that classifies patients as either high risk or low risk - 
high risk being those aged ≥ 3 years at diagnosis, with metastatic dissemination and/or ≥ 
1.5cm
2
 residual tumour following surgical resection, or < 3 years of age at diagnosis, and 
those of average risk being ≥ 3 years of age at diagnosis, without metastatic dissemination, 
and ≤1.5cm2 residual tumour following surgical resection (DeSouza, Jones, Lowis, & Kurian, 
2014; Klesse & Bowers, 2010; Pizer & Clifford, 2008). Patients receive a combination of 
therapies, depending on ‘risk’, including surgical resection, craniospinal radiation, and a 
combination of chemotherapeutic agents (Wlodarski & Jozwiak, 2008). While the use of 
combination therapy has greatly improved patient survival, serious long-term post-treatment 
related health issues are common due to the aggressive nature of treatment. Given the current 
risk-based approach (for determining treatment) does not account for the molecular 
heterogeneity and the variability in outcome associated with each sub-group, some patients 
may receive inadequate treatment, while others receive unnecessarily aggressive treatment. 
This highlights the importance of a therapeutic approach based on molecular sub-group and 
patient prognosis (Northcott et al., 2011), and the need to develop therapies that are sub-
group specific. 
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SHH and WNT pathway inhibitors have been developed and some are currently utilised in 
the clinic for cancer treatment. Such targeted therapies would be appropriate in treating 
medulloblastoma, given the variation in tumour responsiveness to current therapies. 
Particularly for the WNT sub-group patients, which have an excellent prognosis and are 
likely to be ‘over-treated’ using current risk stratification, patients would greatly benefit from 
less aggressive therapies that produce less detrimental side effects. In brain tumours, several 
clinical trials of drugs targeting multiple components of the WNT signalling pathway are 
currently underway (MacDonald, Aguilera, & Castellino, 2014). Additionally, the SMO 
inhibitor; vismodegib (GDC-0449), is an FDA approved treatment for basal cell carcinoma 
that is currently being trialled for SHH medulloblastoma (DeSouza et al., 2014; MacDonald 
et al., 2014; Remke, Ramaswamy, & Taylor, 2013).  The effectiveness of such therapies in 
medulloblastoma would be a major step towards improving patient outcome. Unfortunately 
for the more complex and aggressive Group 3 and Group 4 tumours, no such targeted 
therapies exist. However, a more comprehensive understanding of the molecular pathogenesis 
will likely identify new potential therapeutic targets, and enable the future development of 
successful therapies that will improve medulloblastoma patient outcome. 
 
1.1 The four core medulloblastoma sub-groups 
It is important to understand the heterogeneity of medulloblastoma tumours at the clinical 
level, as well as at the molecular level. An overview of clinical and molecular features of 
each of the sub-groups is presented in Table 1. The recognition that distinct genetic profiles 
exist amongst medulloblastoma tumours, has galvanised research in the field and 
revolutionised the understanding of medulloblastoma pathogenesis, identifying at least four 
core molecular sub-groups. Together, transcriptome, mutation, and cytogenetic analyses have 
identified sub-group specific alterations, and presented numerous candidate tumour 
suppressors and oncogenes for each sub-group that required additional analysis. 
 
To elaborate on these sub-groups; both SHH and WNT medulloblastoma tumours are linked 
to over-activation of the respective signalling pathways, with numerous mutations being 
implicated in tumour development (Remke et al., 2013; Taylor et al., 2012). Both are 
relatively well characterised with a clear understanding of the mechanisms involved in 
tumourigenesis (for review, see (Huse & Holland, 2010). Over-activation of either of these 
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pathways is sufficient in tumour initiation, and is the result of mutations to intermediates 
along the respective signalling pathways (Figure 1). Inactivation mutations to Suppressor of 
Fused (SUFU) or Patched receptor (PTCH1), or activation mutations of Smoothened (SMO), 
constitutively activate the sonic hedgehog signalling pathway with consequent over-
expression of target oncogenes such as MYC family oncogenes (Huse & Holland, 2010; 
Jones et al., 2012; Northcott, Taylor, et al., 2012). Similarly, aberrant activation of the WNT 
signalling pathway leads to development of WNT tumours. Mutations to both the 
Adenomatous polyposis coli (APC) and beta-catenin (CTNNB1) genes cause constitutive 
activation of the WNT signalling pathway, leading to β-catenin accumulating in the nucleus 
and activating target oncogenes such as MYC and Cyclin D1 (Huse & Holland, 2010; 
Northcott, Taylor, et al., 2012).  
 
 
 
 
 
 
 
 
 
Figure 1. Sonic Hedgehog (SHH) and Wingless (WNT) signalling pathways 
The SHH and WNT signalling pathways, shown above, have both been implicated in 
medulloblastoma pathogenesis. Mutations to key pathway intermediates are 
associated with aberrant over-activation of the respective pathways, and are 
associated with SHH and WNT medulloblastoma tumours. In the SHH signalling 
pathway, mutations resulting in the inactivation of PTCH1 and/or SUFU, or 
activation of SMO cause aberrant SHH signalling. Along the WNT pathway, loss 
and gain of function mutations to APC and/or CTNNB1 (encoding β-catenin) cause 
aberrant pathway signalling. Both result in over-expression of target oncogenes.  
Figure adapted from (Huse & Holland, 2010) .  
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Murine models have been invaluable in understanding the biology of these medulloblastoma 
tumours, and from a translational perspective, they are crucial in the development of pre-
clinical trials that may lead to the development of much needed targeted therapies. Currently, 
there are verified mouse models representing SHH, WNT, and Group 3 medulloblastoma 
(Pöschl et al., 2014), but none for Group 4. There are a number of mouse models with various 
alterations to the SHH pathway that have been useful in conducting pre-clinical trials for 
SHH  medulloblastoma (Pöschl et al., 2014). Similarly, WNT medulloblastoma,  mouse 
models with mutant CTNNB1 in combination with mutant TP53, have been generated to 
better understand tumour biology, with potential use as models for testing new therapies for 
WNT medulloblastoma (Gibson et al., 2010; Lau et al., 2012; Pöschl et al., 2014; Remke et 
al., 2013). Only a single verified murine representation of Group 3 medulloblastoma exists, 
with aberrant MYC expression (Swartling et al., 2010), and unfortunately no mouse model 
that is representative of Group 4 medulloblastoma currently exists (Pöschl et al., 2014) 
limiting the development of targeted therapies for one of the most aggressive and metastatic 
sub-groups. In the future, overexpression of putative Group 4 medulloblastoma oncogenes, 
such as DACH1, may be appropriate for consideration for the development of mouse models 
representative of Group 4 medulloblastoma. 
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Table 1. Summary of key features of the four core medulloblastoma sub-groups 
Summarised from Min, Lee, Kim, and Park (2013); Northcott, Korshunov, Pfister, and Taylor 
(2012); Northcott, Schumacher, et al. (2012); Northcott, Taylor, et al. (2012); Schroeder and 
Gururangan (2014). 
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1.2  Group 3 and Group 4 medulloblastoma  
Group 3 and Group 4 medulloblastoma tumours have the highest overall prevalence, poor 
prognosis, and highest frequency of metastasis (Table 1 and Figure 2). Despite their 
aggressive nature and frequent occurrence, the molecular pathogenesis of these tumours is 
not completely understood. There are recurrent abnormalities, including mutations to genes 
that are associated with chromatin remodelling and overexpression of genes associated with 
neuronal differentiation in Group 4, and retinal development in Group 3 (Taylor et al., 2012), 
and frequent amplification of MYC/MYCN which is an indicator of poor prognosis 
(Korshunov et al., 2012; Roussel & Robinson, 2013). There are also characteristic recurrent 
chromosomal rearrangements, the most common being those that involve chromosome 17, 
particularly frequent in Group 4 medulloblastoma (Northcott, Schumacher, et al., 2012). 
While patients with i17q tend to have a poorer outcome, the biology behind this is not known.  
 
 
Figure 2. Distribution of sub-group specific survival, occurrence, and metastasis  
(a.) Patient survival across the four medulloblastoma sub-groups. Group 3 and Group 
4 having the worst survival outcome, followed by SHH, and WNT. (b.) 
Representation of occurrence of each sub-group, Group 4 is most frequently 
diagnosed, followed by SHH and Group 3, and WNT being the least common. (c.) 
Presence of metastatic disease in each of the four sub-groups. Metastasis is most 
common amongst Group 3 and Group 4, and rare in SHH and WNT.  (Image adapted 
from Kool et.al., 2012). 
 
What appears to be most significant in these tumours however, are alterations involving 
epigenetic modifiers, MLL2 and MLL3, as well as KDM6A and KDM6B (Li, K.K-W., Lau, 
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K.M., Ng, H.K., 2013;  Parsons et al., 2011; Schroeder & Gururangan, 2014) . The consistent 
recurrent alterations to epigenetic modifiers are likely to have a critical role in Group 3 and 
Group 4 medulloblastoma pathogenesis. Additionally, a change in expression of a number of 
genes in medulloblastoma has been associated with changes in methylation patterns, pointing 
to potential players in medulloblastoma pathogenesis (Hovestadt et al., 2014). 
 
1.3  Potential mechanisms involved in Group 3 and Group 4 medulloblastoma 
pathogenesis 
The low frequency of recurrent mutations to common cancer-associated genes suggests an 
additional level of complexity in medulloblastoma tumours, potentially involving epigenetic 
regulatory mechanisms at the DNA, histone, and mRNA level (Dubuc et al., 2013; Lindsey, 
Anderton, Lusher, & Clifford, 2005; Uziel et al., 2009). It is evident that alterations to 
chromatin modifier genes are present in all sub-groups (for review see Jones, Northcott, 
Kool, and Pfister (2013)). Most commonly identified across all sub-groups were mutations to 
the methyltransferase gene MLL2, producing a truncated and non-functional protein (Parsons 
et al., 2011). Sub-group specific alterations to other epigenetic modifying genes are also 
observed, with both Group 3 and Group 4 showing characteristic alterations that generally 
result in elevated methylation of Histone 3, lysine 27 (H3K27me3). In Group 4, there are also 
recurrent mutations to the Histone 3 Lysine 27 (H3K27) histone demethylase, KDM6A, 
which produce a non-functional protein (Dubuc et al., 2013). In Group 3 WNT tumours, 
SMARCA4 mutations are common, while in SHH sub-group tumours, alterations to the 
nuclear receptor co-repressor (N-CoR) complex are prevalent (Jones et al., 2013).  
 
Such recurrent changes inevitably impact on the epigenetic regulation of downstream tumour 
suppressor and oncogenes. In support of this, a recent analysis by Hovestadt et al. (2014) 
assessed DNA methylation and gene expression levels across all medulloblastoma sub-
groups, and demonstrated that level of expression was  correlated to methylation status of 
numerous genes (Hovestadt et al., 2014). This insight provides a better understanding of the 
importance of epigenetic alterations in medulloblastoma tumourigenesis.  
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Additional mechanisms of genetic regulation at a post-transcriptional level have an equally 
important role in regulation of gene expression. microRNAs are of note here, and will be 
discussed below in section 3.0. 
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2.0 DACHSHUND HOMOLOG1 
The Dachshund Homolog 1 (DACH1) gene is a homolog of the Drosophila dac gene, a 
regulator of cell fate determination in Drosophila eye, limb, and brain development. Dac is 
an important component of the Drosophila retinal determination gene network (RDGN) for 
specifying of retinal cell fate and promoting photoreceptor differentiation and programming 
retinal progenitor cells (Atkins et al., 2013; Davis, Mardon, et al., 2001; Mardon, Solomon, & 
Rubin, 1994). Mammalian homologues of dac -DACH1 and DACH2- show similar function 
in the regulation of cell fate determination and cell proliferation, and are both important in 
embryonic development, with some redundancy in their role (Davis, Shen, Sandler, Heanue, 
& Mardon, 2001). In mice DACH1 is critical for post-natal survival and development and 
lethal when not expressed, with homozygous DACH1 knockout mice not surviving past 
postnatal day one (Davis, Mardon, et al., 2001).  
 
In humans, the DACH1 gene, 429,233 bases long, is located on chromosome 13q22, and has 
three alternative transcripts. The main DACH1 isoform is translated into a 97kDa protein 
(Davis, Shen, Heanue, & Mardon, 1999). There are two functional domains, located at the C-
terminus (DachBox-C) and N-terminus (DachBox-N) (Tavsanli et al., 2004), and these 
binding domains enable DACH1 to modulate transcription by direct DNA binding or 
interaction with other proteins, regulating cell function in a context-dependent manner 
(Tavsanli et al., 2004; Zhou et al., 2010).   
 
The context in which DACH1 is expressed varies, but the major functions include regulation 
of cell proliferation and growth, and regulation of cell migration. Evidently, aberrant 
expression of DACH1 has implications in the pathogenesis in several cancer types. 
 
2.1  DACH 1 as a Tumour Suppressor 
Reduced expression of DACH1 is a common feature in many cancers, and is accompanied by 
changes in cell function including increased cell proliferation, migration, and tumour 
progression. The tumour suppressive behaviour of DACH1 is well described in breast cancer, 
where it also has clinical relevance, with reduced expression of DACH1 associated with 
tumour progression and metastasis, and poor survival (Desmond et al., 2014; K. Wu et al., 
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2006). Additional studies have led to the identification of other cancers with reduced DACH1 
expression, including prostate cancer, lung cancer, and gastrointestinal cancers, as well as 
others.  
 
In breast cancer, DACH1 is linked to the regulation of cell cycling and cell proliferation by 
antagonizing transcription factors such as c-Jun and FOXM1 and blocking DNA synthesis 
and target gene expression associated with cell cycling (K. Wu et al., 2007; Zhou et al., 
2010). Additionally, DACH1 demonstrates anti-migratory function via inhibition of IL-8 to 
repress pro-metastatic oncogenes MYC, RAS, and ErbB2 in breast cancer (Kongming. Wu et 
al., 2008), and blocking YB-1 transcription factor to maintain E-cadherin expression and 
epithelial phenotype (Wu et al., 2014)  
 
Several studies have confirmed that restoring DACH1 expression results in reduced DNA 
synthesis, cell proliferation, contact-independent growth, cell growth, and reduced tumour 
size in cell lines and in mice (Wu et al., 2014 Wu et al., 2008, Wu et al., 2014., Yan et al., 
2014)  . In addition, altered TGF-β signalling is associated with loss of DACH1, showing 
increased expression in early stages of cancer, and reduced expression in advanced invasive 
cancers (Wu et al., 2014, Yan et al., 2014). . 
 
DACH1 is also involved in regulating epithelial-mesenchymal transition (EMT), and is 
implicated in metastatic progression. Briefly, DACH1 repression of YB-1 inhibits induction 
of transcription factors such as ‘Snail’ which regulate expression of epithelial marker E-
cadherin as well as other targets (Wu, K., et al., 2014). Ultimately, repression of Snail via 
YB-1 enables expression of E-cadherin and maintains a non-invasive epithelial phenotype. 
DACH1 association with EMT also extends to the inhibition of TGF-β signalling, which is 
lost in later stage cancers and is associated with EMT and gaining invasiveness (Yan et al., 
2014). These proposed mechanisms of DACH1 and EMT are outlined in Figure 3. 
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Figure 3. Mechanisms of DACH1-mediated inhibition of Epithelial-
Mesenchymal Transition (EMT): Expression of DACH1 inhibits TGF-β signalling 
in later-stage cancers, and also represses the Y-Box1 transcription factor. These 
block the expression of transcription factor Snail, an inhibitor of E-cadherin, 
enabling the cell to maintain expression of the epithelial marker E-cadherin.  
 
2.2  DACH1 as an oncogene 
Consistent with the pleiotropic properties of DACH1, there are cancers that show elevated 
DACH1 expression, often associated with advanced cancers with poor prognosis. Higher 
levels of DACH1 are associated with cancer progression in ovarian cancer, pre-invasive 
colorectal tumours (colorectal adenomas) and colorectal carcinomas, and leukaemia’s (Lee et 
al., 2012; Liang et al., 2012; Vonlanthen et al., 2014).  
 
Various studies suggest that the level of DACH1expression is associated with tumour stage 
and progression, with clinical relevance for predicting patient prognosis. In ovarian cancer, 
DACH1 is associated with reduced TGF-β expression, and increased cell proliferation (Sunde 
et al., 2006), and also shows relevance to tumour stage, with increasing levels present as 
tumours progress towards metastasis (Liang et al., 2012). Similarly, in colorectal tumours, 
DACH1 is predicted to have an important role in tumourigenesis. Analysis of transcription 
factor expression in colorectal adenomas and colorectal cancer indicated that DACH1 may be 
important in tumour progression, with increased DACH1 in pre-invasive tumours that is 
associated with highly proliferative cells (Liang Wu et al., 2014). Although the mechanisms 
underlying DACH1’s role as an oncogene have not been fully explored, in hematopoietic 
cells at least, elevated DACH1 has been linked to abnormalities in cell cycling and cell 
differentiation (Lee et al., 2012).  
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2.3  DACH1 expression in medulloblastoma 
Gene expression profiling of a series of human medulloblastoma revealed that DACH1 shows 
elevated expression across all medulloblastoma sub-groups compared to normal cerebellum. 
DACH1 is most highly expressed in Group 4 (Figure 4.). Additionally, a recent study 
investigated the level of gene expression across all medulloblastoma sub-groups, DACH1 
included, according to methylation status. This showed that increased expression of DACH1 
is associated with reduced methylation in medulloblastoma, and was highly associated with 
Group 4 medulloblastoma (Hovestadt et al., 2014). Currently, the precise mechanisms driving 
the overexpression of DACH1 in Group 4 medulloblatoma have not been investigated.  
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Figure 4. DACH1 expression across all sub-groups 
DACH1 expression is elevated across all four medulloblastoma sub-groups compared 
to normal cerebellum, highly expressed in Group 4 medulloblastoma (Adapted from 
Mark Remke, University of Toronto, Pers Comm). 
 
2.4  Regulation of DACH1 expression 
The level of DACH1 expression appears to be an important factor in cancer progression; 
however the mechanisms involved have not been fully described for all cancers. Epigenetic 
mechanisms have been proposed and are generally the most frequent abnormalities that 
account for aberrant DACH1 expression. Promoter methylation is seen amongst several 
cancers that show reduced DACH1 expression (Liang Wu et al., 2014; Yan et al., 2013; Yan 
et al., 2014; H. Zhu et al., 2013), and indeed in medulloblastoma, hypomethylation of the 
DACH1 gene is associated with overexpression (Hovestadt et al., 2014). Epigenetic 
alterations directly affecting the DACH1 gene, combined with frequent alterations to 
epigenetic modifiers in Group 3 and Group 4 medulloblastoma that may also impact DACH1 
expression is consistent with a major role for epigenetic modulation of DACH1 expression in 
medulloblastoma pathogenesis. One important epigenetic mechanism that may be involved in 
modifying DACH1 expression is post-transcriptional regulation by microRNAs. 
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3.0  MicroRNA 
MicroRNAs (miRNAs) belong to a class of small non-coding RNA molecules approximately 
22 nucleotides in length, and are recognised as important regulators of cell function. Their 
biogenesis is outlined in Figure 5. Briefly, in the nucleus miRNAs are transcribed from the 
respective miRNA gene by RNA polymerase II, into long primary microRNAs (pri-miRs). 
Cleavage by the ribonucleases Drosha and Pasha (DGCR8) generates a hairpin pre-cursor 
miRNAs (pre-miR) that are then exported from the nucleus. The pre-miRs are then further 
processed by the ribonuclease Dicer and transactivation-responsive RNA-binding protein 
(TRBP) into two short single stranded miRNAs- leading and passenger, the latter of which is 
considered non-functional. Once associated with the RNA-induces silencing complex, the 
‘leading’ strand guides this complex along the target mRNA where binding will initiate target 
degradation or repression (see reviews Fabbri, Croce, & Calin, 2008; Finnegan & Pasquinelli, 
2013).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The typical miRNA biogenesis pathway 
miRNAs are transcribed by RNA polymerase II, and processed in the nucleus by 
various ribonucleases, into premature miRNA (pre-miR). The pre-miR is transported 
from the nucleus and undergoes further modification to generate two single stranded 
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RNAs, one of which will interact with the RISC complex and initiate repression of 
translation of target degradation (Finnegan & Pasquinelli, 2013). 
 
3.1 microRNAs and cancer 
miRNAs are capable of binding with high specificity to target mRNAs to regulate post-
transcriptional gene expression. Specifically, miRNAs bind to their target via Watson-Crick 
base-pairing, recognising a seed sequence within the 3’untranslated region (UTR) of a target 
mRNA (Doench & Sharp, 2004). Such binding targets mRNA for degradation or by blocking 
translation. This mechanism of post-transcriptional modification has provided new insight 
into an additional level at which gene expression can be regulated, and has demonstrated their 
importance in regulating normal cellular processes, as well as their role in tumourigenesis. 
miRNAs have the capacity to function in a similar manner to tumour suppressors and 
oncogenes when aberrantly expressed and are collectively referred to as oncomirs (Cho, 
2007; Esquela-Kerscher & Slack, 2006). A comparison between normal and abnormal 
miRNA expression is shown below in Figure 6. 
 
So far, a number of microRNAs have been identified as key determinants in cancer, many of 
which share a common role in different cancer types. For example, the over-expression of 
miRNAs such as miR-155 and the miR-19~72 cluster repress tumour suppressors leading to 
overexpression of oncogenes such as MYC. Others, such as miR-21 are functionally involved 
in cancer progression and are also markers of poor prognosis (Cho, 2007; Huang et al., 2013; 
S. Zhu et al., 2008). A more comprehensive understanding of the functional importance of 
such miRNAs in cancer, will be invaluable for better understanding the role of these 
molecules not only in the context of disease, but also in normal cellular physiology (Kong, 
Ferland-McCollough, Jackson, & Bushell, 2012).   
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Figure 6. The normal and abnormal behaviour of microRNAs 
(a.) The normal function of microRNA, regulating cellular processes by bocking 
translation of specific target genes. (b.) Tumour suppressive role of miRNA is lost due 
to deregulated miR expression resulting in the aberrant over-expression of oncogenes. 
(c.) A gain in oncogenic microRNA expression results in abnormal degradation of the 
tumour suppressive targets. (Image taken from Huang et al., 2013) (DeSouza et al., 
2014) (DeSouza et al., 2014) (DeSouza et al., 2014) (DeSouza et al., 2014)  
 
3.2 microRNA and medulloblastoma 
The first study miRNA study profiling medulloblastoma tumours was conducted by Ferretti 
et al. (2009), and identified a number of over- and under-expressed microRNAs in 
medulloblastoma tumours and cell lines, as compared to normal cerebellum. Many 
microRNAs demonstrated potential tumour suppressive activity, including miR-9 and 
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miR125a. When transfected into the medulloblastoma cell line D283, both induced changes 
in cell proliferation and increased cell apoptosis (Ferretti et al., 2009).  
 
Continued efforts have identified numerous other candidate miRNAs in medulloblastoma 
pathogenesis, and have focused on determining the functional significance of these miRNAs, 
as well as identifying sub-group specific miRNAs that may provide prognostic markers. miR-
124 is a tumour suppressive miRNA in medulloblastoma, and loss of expression is associated 
with uncontrolled cell proliferation as a result of increased Cyclin-Dependent Kinase 6 
(CDK6) expression. Evidently, increased miR-124 is capable of silencing CDK6 expression, 
and has the potential as a therapeutic to block tumour growth (Silber et al., 2013). Similarly 
miR-22 is also down-regulated in medulloblastoma. Re-introducing miR-22 by transfection 
increased apoptosis in-vitro, and also in-vivo, as well as reducing tumour size in xenograft 
models, which was hypothesised to be, at least in part, due to targeting of the 3’-
phosphoadenosine 5’-phosphosulfate transporter 1 (PPAST1) gene (Xu et al., 2014).  
 
Additionally, over-expressed miRNAs in medulloblastoma have also been identified. A study 
by Genovesi, Carter, Gottardo, Giles, and Dallas (2011) compared miRNA profiles between 
medulloblastoma and humans neural stem cells, a predicted cell of origin in Group 3 and 
Group 4 medulloblastoma, and reported  frequent up-regulation of miRNAs  that are involved 
in regulation of neuronal migration and signalling. Several others have an apparent role in 
metastasis. For example, the miR-183~96~182 cluster is associated with the more aggressive 
medulloblastoma tumours, with  miR-182 in particular, being capable of inducing an 
invasive/metastatic behaviour in vitro, and is associated with tumour invasion to surrounding 
tissue in mouse models over-expressing miR-182 (Bai et al., 2012). A further study noted 
changes in gene expression, specifically an up-regulation of transcription factors involved in 
the regulation and promotion of epithelial-mesenchymal transition (EMT). This suggests that 
the miR183~92~182 cluster may confer changes in invasiveness via epithelial-mesenchymal 
transition (EMT) (Weeraratne et al., 2012). The EMT pathway is one which has been well 
described for its role in tumour metastasis, and is discussed below.  
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3.3  Epithelial-mesenchymal transition (EMT) 
The metastatic process refers to a sequence of events that occur as tumour cells gain the 
ability to invade surrounding tissue and disseminate within the body. These changes in cancer 
cell phenotype are the result of changes in gene expression leading to loss in cell adhesion, 
gaining mobility, and gaining the capacity to disseminate (Nguyen & Massagué, 2007). EMT 
involves a complex network of signalling molecules, transcription factors, and microRNAs, 
which regulate the transition of epithelial cells towards a mesenchymal phenotype, and the 
development of features that favour metastatic dissemination. Thus aberrant activation of 
EMT has been implicated as an early process in metastatic cancer (D'Amato, Howe, & 
Richer, 2013). 
 
3.3.1  microRNAs, EMT, and metastasis 
There is abundant evidence for the crucial role of miRNAs in all stages of cancer 
pathogenesis. In metastasis, the important regulatory role of miRNA, and the impact of 
deregulated microRNA expression on metastatic progression, has been well documented. The 
importance of microRNAs in the regulation of epithelial-mesenchymal transition and 
metastasis will be the focus here. 
 
EMT is a dynamically regulated process and there are multiple levels through which 
expression can be regulated. microRNAs are key, and their loss or gain of expression has 
implications on EMT and metastasis. Figure 7 highlights some of the important miRNA 
regulators in EMT. To elaborate on some of these; expression of both miR-21 and miR-9 
promote metastasis, with miR-21 promoting invasiveness and metastasis in many cancers 
(Cottonham, Kaneko, & Xu, 2010; D'Amato et al., 2013; Huang et al., 2013). Meanwhile 
miR-9 directly controls E-cadherin expression as a pleiotropic pro-metastatic oncogene (Ma 
et al., 2010; Zhang & Ma, 2012). Conversely, there are miRNAs whose expression can 
suppress EMT, such as the miR-200 family whose role in metastasis will be described below.  
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Figure 7. miRNA expression in EMT 
 Several microRNAs are important in maintaining EMT, whose expression may be 
oncogenic and maintain a mesenchymal phenotype, or tumour suppressive whose 
expression maintains epithelial phenotype.  Expression of these miRNAs determines 
whether the cell maintains an epithelial or a mesenchymal phenotype. (Image adapted 
from D’Amato et al., 2013). 
 
3.3.2  The miR-200 family and miR-200b in EMT 
The miR-200 family consists of five members; miR-200a, miR-200b, miR-200c, miR-429, 
and mir-141, belonging to two clusters on chromosome 1p36 (miR-200b/c and miR-429), and 
12p13 (miR-200a and miR-141). They share highly conserved seed sequences which differ 
by only a single nucleotide (Feng, Wang, Fillmore, & Xi, 2014) (Figure 8). 
 
 
 
 
 
 
Figure 8. The miR-200 family members have two conserved seed sequences 
Two clusters of the miR-200 family; miR-200b/c/429 and miR-200a/141, share seed-
sequences differing by a single nucleotide. (Sequences obtained from miRBase, 2014). 
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In cancer, miR-200 functions as an important tumour suppressor. Loss of expression of the 
miR-200 family is evident in many cancers, and is associated with poor survival, increased 
cell proliferation, and in particular, an invasive/metastatic phenotype (Hailin et al., 2013; 
Men, Liang, & Chen, 2014). Members of the miR-200 family are involved in the regulation 
of EMT and maintaining an epithelial phenotype, with loss of expression most commonly 
associated with a metastatic phenotype (Feng et al., 2014; Park, Gaur, Lengyel, & Peter, 
2008). Reduced expression of miR-200b may be a consequence of altered epigenetic 
mechanisms causing promoter hypermethylation affecting the miR-200b cluster which is 
consistent with reduced expression in medulloblastoma.  
 
 Members of the miR-200 family specifically regulate the transcription factors (ZEB1 and 
Zeb2), and form a negative regulatory feedback loop to regulate expression of the epithelial 
cell adhesion molecule E-cadherin (Ding, 2014). To elaborate, ZEBs are negative regulators 
of E-cadherin, and expression results in loss of the epithelial marker E-cadherin, which is 
evident during EMT (Barry et al., 2008; Korpal, Lee, Hu, & Kang, 2008). miR-200 family 
members are inhibitors of ZEBs, and  their expression maintains epithelial phenotype. 
Likewise ZEBs negatively regulate miR-200 and maintain mesenchymal cell phenotype. A 
simplified overview of miR-200 role in EMT is presented below in Figure 9. 
 
 
 
 
 
 
 
Figure 9. Simplified overview of the regulatory role of miR-200 in EMT  
In epithelial cells; ZEB1 and ZEB2 are EMT-inducing transcription factors regulated 
by miR-200, and repress the expression of E-cadherin. In epithelial cells, the miR-
200 family inhibits the expression of ZEB1 and ZEB2. Ultimately this enables 
expression of E-cadherin and maintenance of the epithelial cell phenotype. 
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Loss of miR-200 expression is predicted to be a vital step in the metastatic process, and 
certainly this phenomenon may be important in highly metastatic cancers such as 
medulloblastoma. Previously, the loss of miR-200 expression has been reported in metastatic 
prostate cancer, breast cancer, colorectal cancer, lung cancer, gastric cancer, and others (Feng 
et al., 2014). Different members of the miR-200 family alone, have been identified as 
potential prognostic markers with a proposed prognostic role in glioma and breast cancer 
(Men et al., 2014; Ye et al., 2014), and are able to regulate invasiveness individually. For 
example, over-expression of miR-200b in prostate and gastric cancer results in reduced 
invasiveness that is predicted to be due to reversal of EMT (Hailin et al., 2013; Williams, 
Veliceasa, Vinokour, & Volpert, 2013a, 2013b). Although miR-200 expression has not been 
investigated in medulloblastoma pathogenesis, given the role of deregulated expression of the 
miR-200 family in promoting metastasis in various contexts suggests that loss of miR-200b 
function may contribute to medulloblastoma pathogenesis and metastasis.  
 
Medulloblastoma tumours have a high propensity to metastasise, with around 30% of 
tumours showing dissemination at diagnosis, linked to poor prognosis (Gerber et al., 2014). 
Therefore, effectively targeting metastatic medulloblastoma cells at a molecular level may 
prove to be a valuable therapeutic. miRNA expression profiling in medulloblastoma cell lines 
within this laboratory has revealed down-regulation of miR-200b in medulloblastoma cell 
lines that are representative of the aggressive Group 3 sub-group, consistent with a potential 
role in metastatic medulloblastoma. Additionally, in-silico analysis of the DACH1 3’-UTR 
(TargetScan Human Release 6.2) revealed a potential binding site for nine miRNA/clusters 
(Figure 10a). miR-200b was one of the miRs identified as having a high probability of 
binding to the DACH1 3’UTR at position 971-978 in the 2689 nucleotide (nt) 3’UTR (Figure 
10b).  
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Figure 10a. TargetScan putative miRNA binding sites 
TargetScan identifies nine clusters of miRNAs with potential binding sites in the 
DACH1 3’UTR. Two have 8-mer binding sites with high probability of binding (hsa-
miR200b/c/429 and hsa-miR-153), while the remaining have a low probability 7-mer 
and 8-mer potential binding sites 
 
Figure 10b. miR-200 family target sequence within the DACH1 3’UTR 
Members of the miR-200 family cluster miR-200b/c/429 have an 8-mer sequence 
within the DACH1 3’UTR, with a high probability of binding. miR-200b is 
highlighted. 
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4.0  SUMMARY  
The exact pathogenic mechanisms driving elevated DACH1 expression are unclear, but 
current evidence suggests elevated DACH1 plays an important role in tumour growth, 
progression, and metastasis. DACH1 is a putative oncogene in medulloblastoma, over-
expressed in all four sub-groups of medulloblastoma, most noticeably in Group 4 
medulloblastoma. Its previous links with metastasis supports the potential role of DACH1 in 
progression of metastatic Group 4 medulloblastoma. In addition, it is possible that the over-
expression of DACH1 is a consequence of aberrant epigenetic regulation, such as loss of 
miRNA regulation. In medulloblastoma, miR-200b is down regulated, and has putative 
binding site within the DACH1 3’UTR, suggesting a potential for miR-200b to be involved in 
regulation of DACH1 expression. 
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4.1  AIMS 
We hypothesise that miR-200b regulates DACH1 and that this relationship is significant in 
aggressive Group 3 and Group 4 medulloblastoma pathogenesis. Our aims therefore are: 
1. To confirm an inverse correlation between DACH1 and miR-200b in 
medulloblastoma cells using quantitative reverse transcription polymerase chain 
reaction to assess miR-200b and DACH1 mRNA. 
 
2. To generate reporter cell lines via stable transduction of a DACH1-3’UTR-lenti-
reporter-GFP virus, and assess the effect of miRNA on reporter protein expression. 
 
 
3. Transiently transfect cells with miR-200b, and assess for any changes in DACH1 
mRNA or protein expression, using qRT-PCR and Western Blot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
5.0  METHODS 
5.1  Cell culture: 
Medulloblastoma cell lines DAOY, UW228, PER547, D283, D341, and D425 cells were 
cultured at 37
o
C, in 5% CO2 . These cells were maintained as follows: 
 
Table 2 Cell line details and culture conditions 
 Cell line details Culture conditions 
DAOY Representative of Sonic 
Hedgehog (SHH) 
medulloblastoma 
(Jacobsen, 1985) 
Adherent cells, grown as a single monolayer  
DMEM (Gibco®, Invitrogen™, 
LifeTechnologies™, Carlsbad, Canada)  + 
10%FCS + 1% Glutamax (Gibco®), 
harvested with 0.05% dissociation reagent 
(TrypsinEDTA) (Gibco®) and subcultured at 
1:20 when cells reached 90% confluence 
UW228 Representative of Sonic 
Hedgehog (SHH) 
medulloblastoma 
(Keles, 1991) 
Adherent cells, grown as a single monolayer 
MEM (Gibco®) + 10% FCS + 1% Glutamax 
(Gibco®), harvested with 0.05% trypsin, 
subcultured 1:20 when cells reached 90% 
confluence 
PER547 Representative of Group 3 
medulloblastoma 
(Holthouse et al., 2008) 
 
Suspension cells (1:6) 
RPMI (Gibco) + 20% FCS + Glutamax 
(Gibco®) + non-essential amino acids 
(NEAA) 100x (Gibco®) + Sodium pyruvate 
(NaP) 100nM (Gibco®)+ 1.8mL 2-
mercaptoethanol (2-ME) (Sigma Aldrich®, 
St. Louis, Missouri), cells were subcultured 
1:6 when 80-90% confluent 
D283 Representative of Group 3 Semi-adherent cells (1:3) 
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medulloblastoma 
(Friedman, 1985) 
MEM (Gibco®) + 20% FCS + 1% Glutamax 
(Gibco®), cells were subcultured when 80-
90% confluent 
D341 Representative of Group 3 
medulloblastoma 
(Firiedman, 1988) 
Suspension cells. (1:3) 
MEM (Gibco®) + 20% FCS + 1% Glutamax 
(Gibco®), cells were subcultured when 80-
90% confluent 
D425 Representative of Group 3 
medulloblastoma 
(He, 1991) 
Semi-adherent cells. 1:5 
Modified MEM (Gibco®) + 10% FCS + 1M 
Hepes (Gibco®), cells subcultured when 80-
90% confluent 
 
Adherent cells were harvested by removing medium then briefly washed in 5-10mL of DPBS 
(Gibco®).  5-10mL of 0.05% dissociation reagent. Cells were incubated for 5 minutes at 
37
o
C  and then mechanically dissociated from plate. Cells were collected in a 5mL tube, then 
diluted 1:20 and re-plated in a T25 flask (nunc) with 5mL of growth medium, or a T75 with 
10mL of growth medium. Note that cells were re-plated while suspended in trypsin.  
 
Semi-adherent/suspension cells were harvested by mechanical pipetting to dissociated cells 
and collected in a 50mL Falcon tube. Cells were split in a 1:3-1:6 ratio depending on growth 
rate. Cells were plated in 1mL of medium in a 24 well plate (nunc).  
 
5.1.1  Countess: cell number and viability  
10µL of harvested cells were aliquoted with 10µL of 0.2% Trypan Blue (TB) (Sigma 
Aldrich®) (1:1 ratio). 10µL was then counted using the Countess™ automated cell counter 
(Invitrogen™, Life Technologies™). 
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5.2  Protein Extraction 
1.0-4.0x10
6
  cells were pelleted in using a HERAEUS Multifuge 35R+ (ThermoScientific, 
Waltham, Massachusetts) at 900rpm for 5 minutes, and resuspended in PBS buffer (-Mg
2+
 
and -Ca
2+
, Gibco®), then re-pelleted. Cells were lysed in 70µL radioimmunoprecipitation 
assay (RIPA) buffer (150mM NaCl, 50mM Tris HCL pH8, 1% NP-40, 0.5% Sodium 
deoxycholate, 0.1% SDS with complete mini EDTA free and phos-stop inhibitors (Roche, 
Switzerland). The Lysate was then centrifuged 13,000rpm for 20minutes at 4
o
C (HERAEUS 
Fresco17, ThermoScientific) to pellet debris, and protein was quantified using a Direct 
Detect™ Spectrometer (Merck Millipore, Billerica, Massachusetts).  
 
5.3  SDS polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting 
Total protein (30µg), was adjusted to 20µl with the addition of 2µl 10x reducing agent and 
5µl 4x loading buffer. Samples were denatured at 70
o
C and run on 3-8% Tris Acetate gel 
(NuPAGE®, Life Technologies™) at 145V for 65 minutes at room temperature, in Tris 
Acetate running buffer. Precision plus protein™ Dual Colour standards (BioRad, Hercules, 
California).  
 
Protein was transferred to BioRad 0.2µM nitrocellulose membrane (1620112) in 1x 
NuPAGE® (Life Technologies™) transfer buffer, 20% methanol, at 30V for 120 minutes, at 
4
o
C. Following transfer, membranes were stained with Ponceau S (0.1% Ponceau S, 7% 
glacial acetic acid) to monitor efficiency of protein transfer. Membranes were subsequently 
blocked for 1 hour at room temperature in blocking solution (5% skim milk powder in 
1xTBS/0.1% Tween-20), and washed 3x5minutes in 1xTBS/0.1% Tween-20.  
 
Primary antibody; rabbit anti-human DACH1 polyclonal antibody (10914-1-AP, raised 
against amino acid residues 350aa in the C-terminus) (Proteintech™, Chicago), was diluted 
1:1000 with 5µL in 5mL  antibody diluent buffer (1% Skim milk powder, 1% BSA in 
1xTBS/0.1% Tween-20) and incubated overnight (O/N) at 4
o
C on a shaker. Membrane was 
washed 3x5min in 1xTBS/0.1% Tween-20. 
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The membrane was incubated with ECL Rabbit IgG, HRP-linked F(ab)2 secondary antibody 
(NA9340V) (GE healthcare, Wisconsin), diluted 1:5000 with 1µL antibody in 5mL of 
antibody diluent, for 1 hour at room temperature.  
 
SuperSignal West Dura Extended Duration Substrate (ThermoFisher Scientific) was used for 
signal detection, and immunoblots were visualised using ChemiDoc MP Imaging System 
(Bio-Rad). 
 
β-actin was used as a loading control; Primary antibody monoclonal anti β-actin antibody, 
mouse (A1978) (Sigma Aldrich®),  and ECL Mouse IgG, HRP-linked F(ab)2 secondary 
antibody (NA9310V) (GE healthcare), diluted 1:5000, incubated at room temperature for 1 
hour each and developed as described above. 
 
5.4  Extraction of total RNA 
In most cases, total RNA (including mRNA and miRNA) was extracted from cell lines using 
a miRNeasy kit (QIAGEN, Cat No: 217004) following the recommended protocol for 
isolation of miRNA-enriched total RNA.  
 
Briefly, cells were harvested as described and pelleted by centrifugation (HERACUS 
Multifuge35R, ThermoFisher) in a 25mL Falcon tube (BD Falcon, USA) at 900rpm for 5 
minutes. Cells were washed once* in 1mL DPBS (Gibco®) (*Adherent cells were washed 
twice) and counted using the Countess automated cell counter (Invitrogen™, Life 
Technologies™) as described. DPBS (Gibco®) was removed and cells were resuspended in 
350-700µL of QIAZOL lysis reagent (QIAGEN). To mix, the suspension was vortexed and 
incubated at room temperature for 5minutes. Lysate was then extracted by adding 70-140µL 
of Phenol-chloroform and incubating at room temperature for 2 minutes, then centrifuged 
12000rpm/15 minutes (HERAEUS Fresco17, ThermoScientific). The upper phase was 
removed (approximately 100µL) and added with 1.5 volumes of 100% ethanol. Washes were 
performed with buffer RWT and buffer RPE and purified RNA was eluted in RNase-free 
water and quantified using nano drop spectrophotometer (ThermoScientific). RNA with a 
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260/280 ratio of >1.8 was considered to be of suitable quality and RNA integrity was further 
assessed by electrophoresis on a 1.5% agarose gel.  
 
5.5  TaqMan® Gene expression assays  
Two-step quantitative reverse transcription polymerase chain reaction (qRT-PCR) was 
performed to assess DACH1 mRNA expression in DAOY, UW228, PER-547, D283, D341, 
and D425. Gene expression assays were performed as per TaqMan® (Applied Biosystems 
ABI®, Life Technologies™) recommended protocol, using 200ng of total RNA in a 20µL 
reaction, and reverse transcribed using SuperScript® VILO™ master mix (Invitrogen™, life 
technologies™) with random primers. 
 
Reverse transcription reactions were prepared using 4µL SuperScript® VILO™ 
(Invitrogen™) master mix with SuperScript® III Reverse Transcriptase and a final 
concentration of 200ng/µL of total RNA. Conditions for RT were as follows:  
 25
o
C 10 minutes 
 42
o
C  1 hour, 40 minutes 
 85
o
C  5 minutes 
 
The cDNA was then used to perform qPCR. Triplicate reactions were prepared with 1.33µL 
of cDNA preparation , 20x TaqMan® gene expression assay for DACH1 (ABI®, Life 
Technologies™, Cat#: 4351372) and GAPDH (ABI® Life Technologies™, Cat# 4331182), 
2x TaqMan® universal PCR master mix (No AmpErase® UNG), and nuclease-free water. 
20µL samples were then plates and run on ABI® 7900HT Fast Real-Time PCR system using 
SDS version 2.3 software (ABI®), and the comparative Ct (Cycle threshold) (ΔΔCt) method. 
Cycling conditions for qPCR were as follows:   
Stage 1 (HOLD)  95
o
C 10 minutes 
 Stage 2 (40 cycles) 95
o
C 15 seconds 
    60
o
C  1:00 minute 
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5.6  TaqMan® microRNA assays  
Total RNA was prepared using an miRNeasy (microRNA extraction) kit (QIAGEN) and 
quantified, as previously described. Total RNA was diluted to 2ng/µL in RNase-free water, to 
give a final concentration of 10ng/µL total RNA per reaction. RNA for reverse transcription 
was prepared in singleplex reactions with miRNA-specific primers for miR-200b (target and 
RNU44 (internal control) and RNU48 (internal control) (ABI®, Life Technologies™, Cat#: 
4427975). TaqMan® miRNA reverse transcription (RT) master mixes (ABI®, Life 
Technologies™) with MuLV RT were prepared as singleplex reactions using specific 5x RT 
primers specific for the miR-200b 3p strand, RNU44 and RNU48.  
 
Per 15µL reaction using, 7µL of master mix was made up as follows 
 0.15µL of 100mM ddNTP 
 1.00µL of 50U/µL MultiScribe™ reverse transcriptase 
 1.50µL of 10x RT buffer 
 0.19µL of 20U/µL RNase Inhibitor  
 4.16µL RNase-free water 
 
MasterMix and RNA were combined at a ratio of 7µL:5µL + 10%, with 7.7µL + 5.5µL.  
12µL of MasterMix plus RNA war combined in a 0.2mL PCR tube, with 3µL of primer and 
gently mixed. 
 
RT was carried out using recommended thermo cycling conditions: 
 On Ice  5 minutes 
 16
o
C 30 minutes 
 42
o
C  30 minutes 
 85
o
C 5 minutes 
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Reverse transcribed miRNA was then used to perform qPCR. These were set up in triplicate, 
with each individual reactions were prepared with 1.33µL of cDNA preparation (1:15 
dilution), 1µL 20x TaqMan® microRNA expression assay for miR-200b, or 1.0µL of 20x 
TaqMan® microRNA expression assay for RNU44/RNU48 (ABI® Life Technologies™, 
Cat#: 4427975), 10.0µL 2x TaqMan® universal PCR MasterMix (No AmpErase® UNG), 
made to a final volume of 20L with 7.67µL of nuclease-free water. The 20µL samples were 
then plates and run on ABI 7900HT Fast Real-Time PCR system using ABI® SDS version 
2.3 software (ABI®, ©2005), and the comparative Ct (ΔΔCt) method. Cycling conditions for 
qPCR were as follows:  
Stage 1 (HOLD) 95
o
C 10 minutes 
 Stage 2 (40 cycles) 95
o
C 15 seconds 
    60
o
C  1:00 minute 
All qRT-PCR data was collected using ABI® RQ manager version 1.2 software (ABI®, 
©2005), and further analysed using Microsoft Excel.  
 
5.7  Lentiviral Transductions 
Transductions for the following were attempted: 
(i)  Cell lines with low levels of mir-200b were transduced with a hsa-miR-200b-
GFP-lenti reporter (Applied Biological Materials (ABM®) Inc., New York City, 
USA) (Cat#: Mh-15262).  
(ii) All cells were transduced with a DACH1-3’UTR-GFP-Lenti reporter virus 
(ABM® Inc., Cat#: MV-05537). See Figure 11a and 11b for vector constructs. 
 
Protocol supplied by ABM® Inc. was followed, with adjustments made for optimisation. 
Following the ABM protocol, cells were seeded the day before transfection at a density of 
0.5x10
5
 cells per well.  
 
On the day of transfection, cells were harvested and pelleted as usual, then resuspended in 
medium containing 8µg/mL of polybrene, and various amounts of viral medium were added. 
Also included were a GFP control lentivirus, and a negative control pLenti-III-Lentivirus  
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(ABM® Inc., Cat#: LVPS87) (Figure 11c). Controls for polybrene toxicity and another of 
uninfected cells were used as controls. Cells were incubated for 24 hours, then medium was 
removed and replaced with normal growth medium. Cells were incubated for a further 48 
hours and then selected for with 2µg/mL of puromycin. A puromycin control was included.  
 
Small adjustments were made to this, including cell numbers- cells were plated at a density 
such that they would be ~80% confluent, 72 hours after transfection (adherent cells were 
seeded at a density of 1.4x10
5
 cells/T25 flask (Nunc), and semi-adherent cells were plated at 
a density of ~1.0x10
5
 cells/well in a 24-well plate (Nunc). Virus was also removed after 3-4 
hours of incubation. Cells were allowed to recover for three days before selection.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
 
 
 
 
 
 
Figure 11a. DACH1-3’UTR-Lenti-reporter-GFP viral vector 
 
 
 
 
 
 
Figure 11b. Lenti-miRa-GFP-hsa-miR-200b viral vector 
 
 
 
 
 
 
Figure 11c. pLenti-III-blank-lentiviral vector 
 
Lentiviruses were obtained commercially from ABM® Inc. All three include a CMV 
promoter, and contain puromycin resistance (Puro
r
) gene for cell selection. DACH1-3’UTR-
GFP-lenti reporter viruses also contain a Green fluorescent protein gene (GFP) linked to the 
DACH1 3’UTR for assessment of reporter expression with high or low miR-200b expression. 
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5.8  Cloning 
5.8.1 Transformation of E. coli  
One Shot® TOP10 chemically competent E. coli (Invitrogen™, Life Technologies™) were 
transformed with 2ng of DACH1 3’UTR lenti-reporter-Luc Vector plasmid (ABM® Inc, 
Cat#:MT-h05537) (Figure 12.). Briefly, cells were combined with plasmid and incubated on 
ice for 30 minutes, transferred to 42
o
C for 30 seconds, and then kept on ice for 2 minutes. For 
recovery, 250µL S.O.C medium was added and cells plus medium were transferred into a 
15mL Falcon tube (BD Falcon) and incubated in a shaker at 250rpm, 37
o
C overnight.  
 
Following overnight incubation, 50µL, 100µL, and 150µL of cells were plated on LB agar 
plates containing Kanamycin (50µg/mL) and incubated at 37
o
C overnight. Plates were then 
stored at 4
o
C. 
 
Two separate colonies were picked and used to inoculate individual 15mL falcon (BD 
Falcon) tubes containing 2 mL of LB broth/50µg/mL Kanamycin. These cells were incubated 
on a shaker at 250rpm at 37
o
C overnight. 100µL of the overnight mini prep culture was added 
to a conical flask containing 100mL of LB/ 50µg/mL Kanamycin broth and cultured at 37
o
C 
overnight.  
 
Following overnight culture, the cells were transferred into two 50mL falcon tubes and 
centrifuged 4000rpm for 10 minutes.  
 
Plasmids from transformed cells containing the DACH1 3’UTR lenti-reporter-Luc plasmid 
(ABM® Inc.), and pre-prepared cells containing pCAG-KPGY Gagpol plasmid, pCAG-
VSVG envelope plasmid, and pCAG-RTR revtat plasmid (supplied by Dr Jacqueline 
Whitehouse) were isolated using Plus midiprep kit (QIAGEN) high efficiency protocol. 
Plasmid DNA quality was then assessed using the nanodrop spectrophotometer (Thermo 
Scientific) and stored at -20
o
C. 
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Figure 12. pLenti-DACH1-3’UTR-Luc-reporter vector 
The pLenti-DACH13’UTR-luciferase-reporter vector was purchased from Applied 
Biological Materials Inc. (ABM). The vector contains a Kanamycin resistance (Kan
r
) 
gene used to select for transformed bacterial colonies, a Puromycin resistance (Puro
r
) 
gene for selecting transduced cells, and a luciferase reporter linked to the 3’UTR for 
assessing reporter expression in the presence of high and low levels of miR-200b. 
 
5.9  Generation of lentivirus 
To generate lentivirus, Human Embryonic Kidney 293T (HEK-293T) cells were transfected 
with reporter and packaging plasmids, according to the following procedure (supplied by Dr 
Jacqueline Whitehouse): 
 
On day one, 3x10
6
 293T cells were plated in a 10cm culture dish with DMEM (Gibco®) + 
1% (v/v) Penicillin/Streptomycin (pen/strep) (Gibco®) 1% (v/v) + 10% (v/v) FCS. 
 
Day 2, plasmid DNA was combined in serum-free DMEM (Gibco®) and vortexed to mix. 
DNA was added at the following amounts: 
 12µg of vector plasmid (DACH1 3’UTR-lenti-reporter-Luc vector) 
 6µg of gagpol plasmid (pCAG-KPGY) 
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 2µg of envelope plasmid (pCAG-VSVG) 
 2µg of revtat (pCAG-RTR) 
 
FuGene 6® transfection reagent (Promega) was diluted in serum-free DMEM and vortexed to 
mix. FuGene and plasmid DNA were combined and added to cells with 8mL of fresh DMEM 
medium (Gibco®) + 1% Pen/Strep (Gibco®) + 1% Glutamax (Gibco®) + 10% FCS, and 
incubated 37
o
C for 24hours.  
 
Day 3, media was removed and replaced with 5mL of DMEM medium (Gibco®) + Pen/Strep 
(Gibco®)+ Glutamax (Gibco®) + 10% FCS, and incubated 37
o
C/5% CO2 for a further 
24hours.  
 
Day 4, 48 hours following transfection, the 48 hour viral supernatant was collected and stored 
on ice at 4
o
C overnight. 5mL of fresh DMEM medium (Gibco®) was added to cells. 
 
Day 5, 5mL of 72 hour viral supernatant was collected and combined with 48 hour 
supernatant, and filtered through a 0.45µm filter syringe, then stored at -80
o
C.  
 
5.10 Transfections 
SiGlo green transfection indicator (Dharmacon, GE Healthcare, Cat#: D-001630-01-20), 
20nmol dry stock, and mirVana hsa-mir-200b-3p mimics 5nmol dry stock (Ambion®, Life 
Technologies™, Cat#:4464066) were resuspended to a final concentration of 50µM, by 
adding 400µL, and 100µL of RNase-free water, respectively. 
 
The Neon® electroporation system (Invitrogen, Cat#MPK5000) was use to conduct 
transfection, using 10µL Neon® tips (Invitrogen, Cat#MPK1096). 10µL of transfected cells 
were plated in 490µL of growth medium to a final volume of 500µL, in a 24 well plate. 
Optimal transfection conditions for D283 and D341 had previously been determined, with 
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successful transfection with 1 pulse at 1350 volts (V), 20 milliseconds (ms). These conditions 
were also found to be optimal for transfection of PER547 and D425. 
 
Following the recommended protocol, cells were plated 1-2 days prior to transfection in 
normal growth medium. The following day cells were harvested and pelleted by 
centrifugation at 400xg for 5 minutes (ThermoScientific). Cells were counted on the countess 
(Invitrogen™), as previously described, and washed in PBS buffer (no MgCl2). Cells were 
resuspended in buffer R (Invitrogen™) to a density of 1.0x107 cells/mL, and mixed well to 
create a single cell suspension. 13µL aliquots of cell suspension were added with 2.6µL (or 
6.5µL) of 50µM of hsa-mir-200b-3p mirVana mimic (Ambion®) (hereafter referred to ‘miR-
200b mimic’) or miRNA negative control#1 (hereafter referred to as ‘control’) (Ambion®) 
and gently pipetted to mix. 10µL of cell mix was electroporated in 5mL of Buffer E 
(Invitrogen™) using conditions of 1350V, 1 pulse, 20ms. Electroporated cells were then 
plated in 490µL of pre-warmed culture medium, with miR-200b mimic/control at a final 
concentration of 20nM or 50nM). A total of 12 wells were plated for both the mimic and 
control. SiGlo was used as a transfection indicator to determine transfection efficiency. SiGlo 
(Dharmafect GE healthcare) was transfected to a final concentration of 20nM in 500µL using 
the same conditions.  
 
Following 24-48 hour incubation, cell fluorescence of SiGlo (Dharmafect GE healthcare) 
transfected cells was assessed using the Tali™ image based cytometer (Invitrogen™). A 
control sample of un-transfected cells and a sample of SiGlo transfected cells were assessed. 
If cell fluorescence was >75%, transfected cells were harvested, and protein and RNA were 
extracted as described above, for downstream mRNA, miRNA, and protein analysis.  
 
5.10.1 Lipofectamine® RNAiMAX transfection 
The recommended protocol was followed for transfection of DAOY cells using 
Lipofectamine® RNAiMAX Lipofectamine transfection (Invitrogen™, Cat#: 13778500). 
 
In separate tubes, 9µL of RNAiMAX (Invitrogen™) or 1.2µL of 50nM SiGlo were diluted 
into 150µL of OptiMEM (Gibco®) reduced serum medium. 150µL of both diluted SiGlo and 
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RNAiMAX were combined in a 1:1 ratio and incubated at room temperature for 5 minutes to 
allow complexes to form. 250µL of combined solution was then added drop-wise to cells, 
into a final volume of 250µL, giving a final concentration of 20nM.  
 
Cells were incubated for at least 24 hours and fluorescence was then assessed using the 
Tali™ image based cytometer (Invitrogen™) as described below.  
 
5.10.2 Tali™ Image based cytometer 
Cells were harvested 24 hours following transfection and fluorescence was assessed by 
transferring a 25µL aliquot of cells onto a Tali™ slide (Invitrogen™). An un-transfected 
sample was assessed to obtain a background measure. Gates were set so that 0% fluorescence 
was detected in control un-transfected cells. Transfected cells were then assessed using Green 
fluorescent detection and a right hand shift of the curve indicated positive transfection. A 
percentage value of fluorescent cells was then obtained. Cells with ≥70% fluorescence were 
used for downstream expression analysis.  
 
5.11 Data analyses 
5.11.1 qRT-PCR expression data 
qRT-PCR data was collected using ABI® RQ manager version 1.2 software, and exported to 
excel for analysis. Relative Quantitation (ΔΔCt) analysis was performed, as previously 
described. Briefly, average Ct values from two to three independent experiments, with two to 
three replicates per-experiment were collected. Average Cts ≥32 were given a value of zero 
to represent no expression.  
 
Normalised expression between the Gene of Interest (GOI), DACH1 and miR-200b, and the 
Internal control GAPDH, and RNU44/RNU48, was calculated as ΔCt value where ΔCt= 
CtGOI – CtInternal Control. For post-transfection analysis, the ΔCt was adjusted to 2
-ΔCt
 and Log2 
transformed to give a value representing normalised expression (target relative to control). 
For the base-line analysis, relative quantitation (RQ) was determined using D283 as a 
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normalised. This was calculated as ΔΔCt= ΔCtGOI – ΔCtnormaliser (D283), and adjusted 2
-ΔΔCt
 and 
Log2 transformed.  
 
Standard deviation (SD) was calculated as the SD between the target and control = (GOI SD
2
 
+ internal control SD
2
)
0.5
. The Ct SD was presented as error bars.  
 
5.11.2 Western blot and protein quantification 
Membranes were probed with primary and secondary antibodies, and protein was detected 
using SuperSignal® WestDura Extended duration substrate (ThermoFisher Scientific). 
Immunoblots were visualised using the ChemiDoc MP imaging system (BioRad), and were 
presented in BioRad ImageLab 5.1 software.  
 
Relative protein was determined by assessing the quantity of DACH1 to the β-actin control. 
Quantity was determined based on band intensity. Normalisation to β-actin was carried out as  
band intensity of DACH1 band-band intensity of β-actin band, and Log2 transformed.  
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6.0  RESULTS 
6.1  An inverse correlation between DACH1 and miR-200b expression in 
medulloblastoma cell lines 
The DACH1 3’UTR contains a putative binding site for miR-200b (see Figure 10.) 
suggesting that miR-200b may target the DACH1 transcript. To address this, miR-200b and 
DACH1 expression were assessed in six medulloblastoma cell lines, using two-step 
quantitative reverse transcription polymerase chain reaction (qRT-PCR). Ct values ≥32 were 
considered negligible or no expression. An inverse correlation between levels of DACH1 
mRNA and miR-200b was detected in 5/6 cell lines, with D425 being the exception (Figure 
13.). 
 
For analysis, expression was normalised against an internal control; GAPDH was the internal 
control used for normalisation of DACH1 expression in all cell lines, RNU44 was used as an 
internal control for miR-200b in D341, PER547, and D283, while RNU48 was an internal 
control in D425. D425 was normalised to the internal control RNU48 due to RNU44 having 
higher Cts compared to the other cell lines. RNU48 also had higher Ct values than RNU44 in 
the other five cell lines, skewing the normalisation of D425. Original, un-normalised Ct data 
(Appendix B.) demonstrates that miR-200b expression is relatively consistent across all cell 
lines, including D425.  
 
The comparative Ct (ΔΔCt) method was used for normalisation of expression, presented as 
DACH1 or miR-200b expression normalised to the appropriate internal control, and relative 
to D283 cell line. This method was previously described by (Livak & Schmittgen, 2001; 
Schmittgen & Livak, 2008). Figure 13 presents the normalised levels of DACH1 and miR-
200b in each of the cell lines that were investigated. A summary of their expression is 
presented in Table 3. 
 
DACH1 protein was detected using western blot to confirm expression at the protein level. 
Consistent with the qRT-PCR data, a prominent band of ~97kDa, the predicted size of the 
DACH1 protein was detected in PER547 and D341, and lower levels of DACH1 protein were 
present in D425 and D283. DACH1 protein was not detected in DAOY or UW228 
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    DACH1 mRNA expression            miR-200b expression 
 
Figure 13. Expression of DACH1 and miR-200b in medulloblastoma cell lines, 
relative to D283. 
An inverse correlation between the expression of DACH1 mRNA and miR-200b was 
evident in the majority of cell lines (5/6). Total RNA and miRNA-enriched RNA were 
extracted from all cells, and expression was assessed using qRT-PCR. Each extraction 
was repeated three times, with two to three replicates for each cell line for each qRT-
PCR experiment. The results were analysed using relative quantitation, with average 
cycle threshold (ct) values normalised against a respective internal control; for DACH1, 
GAPDH was used as the internal control in all cell lines, and for miR-200b, RNU48 
was used as an internal control for D425, while RNU44 was used as the internal control 
for the remaining cell lines. Normalised expression was determined relative to D283.  
 
To highlight the inverse correlation, no cut-off ct value was applied here, however 
DACH1 expression in DAOY, and miR-200b expression in PER547, D283, D341, and 
D425 all had ct values ≥32, which was designated as ‘no expression’. The error bars 
represent standard deviation (SD) between ct values from each independent experiment.  
SD was calculated as (SD DACH1
2
 - SD GAPDH
2
)
0.5
 or  (SD miR-200b
2
 – SD 
RNU44/48
2
)
0.5
.  
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DACH1 protein expression 
 
Figure 14. DACH1 protein expression in six representative medulloblastoma cell 
lines with quantitative analysis of protein expression 
(a.) DACH1 protein was detected in the four cell lines that also showed elevated 
DACH1 mRNA expression, and was not detected in DAOY and UW228. β-actin was 
used as a loading control, and indicated that higher levels of protein were loaded for 
DAOY, UW228, and D283. (b.) Additional quantitative analysis of DACH1 protein 
expression was performed, relative to β-actin. PER547 and D341 expressed high levels 
of DACH1, D425 and D283 expressed lower levels, while no DACH1 protein was 
detected in DAOY and UW228.  
 
 
DAOY  UW228 PER547 D283 D341 D425 
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Table 3.  Simplified summary: an inverse correlation exists between DACH1 and miR-
200b 
 DACH1  miR-200b 
DAOY Low High 
UW228 Low High 
 
PER547 High Low 
D283 High Low 
D341 High Low 
D425 High Low 
 
A summary of DACH1 and miR-200b expression, showing an inverse correlation between 
DACH1 and miR-200b that is based on average Ct data (Appendix B). 
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6.2  Addressing the inverse correlation between DACH1 and miR-200b 
6.2.1  Stable transductions with Lentivirus 
Lentiviral transductions using commercially obtained lentiviruses DACH1 3’UTR Lenti-
Reporter-GFP virus, and Lenti miRa-GFP-hsa-mir-200b virus (Applied Biological Materials 
Inc. (ABM) were attempted in cell lines with low endogenous miR-200b expression. 
However, due to unexpected problems with commercially purchased DACH1-3’UTR-GFP-
Lenti reporter viruses, reporter cell lines were not generated. This was due to evidence of 
bacterial contamination of viral stocks. Contamination was suspected following high levels of 
cell death occurring 72-96 hours after transductions but prior to puromycin selection.  
Importantly, this occurrence was only identified in cells that were inoculated with the 
purchased lentivirus.  
 
To further confirm the source of contamination, culture medium was inoculated with viral 
medium, and produced visible growth of bacteria 72-96 hours after inoculation, which was 
not detected in medium alone. Cells were cultured in 1% Penicillin/Streptomycin and 
maintained post-transduction however this did not prevent outgrowth of bacteria. 
Consequently a new approach was needed in order to assess the potential association between 
DACH1 and miR-200b.  
 
DACH1-3’UTR-Luc-lenti reporter plasmids (Figure 12.) were purchased from ABM Inc. and 
used to generate lentiviruses. DAOY cells proved easy to transduce and produced puromycin-
resistant colonies. This indicated that the virus was capable of infecting cells and was then 
applied to semi-adherent cells with low miR-200b expression. These cells proved difficult to 
transduce and puromycin resistant colonies were not detected after repeat attempts. Due to 
time constraints, this protocol was not optimised, and therefore no data were collected. 
 
6.2.2  Transient transfection of selected medulloblastoma cell lines 
The difficulties associated with the viral transduction strategy described above, necessitated 
an alternative approach for the manipulation of miR-200b levels in medulloblastoma cell 
lines. A second approach to assessing whether DACH1 was targeted by miR-200b involved 
transient transfection of mir-200b mimic and antagomirs. Cell lines with low levels of 
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DACH1 expression, and high levels of miR-200b expression based on raw Ct values 
(Appendix B), were to be transfected with miR-200b antagomirs, however, as described in 
section 6.2.5, no optimised protocol was developed for these cell lines and transfection with 
miR-200b antagomirs was not conducted. Cell lines with high levels of DACH1 expression, 
and low miR-200b expression based on raw Ct values (Appendix B), were selected for 
further analysis. These cell lines included D341, D425, PER547, and D283. 
 
Firstly, optimal transfection conditions were tested for PER547 and D425, while previously 
optimised conditions were available for D283 and D341. Transfection conditions used for 
D283 and D341 also produced the highest transfection efficiency in PER547 and D425. To 
determine transfection efficiency, cells were transfected with SiGlo fluorescent green 
transfection indicator at a final concentration of 20nM, and fluorescence was assessed 
following a 24 hour incubation. Further analysis was performed when transfection efficiency 
of SiGlo control cells was ≥75%.   
 
Cells were transiently transfected with a final concentration of 20nM of hsa-mir-200b-3p 
mirVana mimic or miRNA negative control#1, and a final concentration of 50nM of hsa-mir-
200b-3p mirVana mimic or miRNA negative control#1.  
 
Protein and miRNA-enriched RNA were extracted at both 24 hours and 48 hours post-
transfection, for expression analysis. 
 
6.2.3  Confirming miR-200b expression post-transfection 
qRT-PCR was used to confirm whether miR-200b expression was restored following 
transient transfection of these cell lines. Successful restoration of miR-200b expression was 
confirmed following transfection with 50nM and 20nM mimic, by calculating Ct averages for 
miR-200b and RNU44/RNU48, and normalising miR-200b expression to RNU44 (RNU48 in 
D425) to obtain a ΔCt value for mir-200b mimic, and negative control transfected cells. 
Normalised miR-200b expression in cells transfected with mir-200b mimic was compared to 
the corresponding cell line transfected with negative control#1. These data were presented as 
Log2 transformed 2
-ΔCt 
values. 
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6.2.4 Determining inhibition of DACH1 by miR-200b 
To address the predicted targeting of DACH1 by miR-200b, hsa-mir-200b-3p stem loop 
mirVana mimics were transiently transfected into 4/6 medulloblastoma cell lines with low 
endogenous miR-200b, and relatively high DACH1 mRNA and protein (Table 3.). Two 
concentrations were selected; 50nM and 20nM 
 
6.2.5 Optimising transfection of adherent medulloblastoma cell line 
The adherent cell lines DAOY and UW228, had higher levels of miR-200b expression and 
lower DACH1 expression based on raw Ct values (Appendix B.), and therefore were selected 
for transfection with hsa-mir-200b-3p mirVana antagomirs (mir-200b antagomirs). 
Identification of optimal NEON transfection conditions for DAOY and UW228 cell lines was 
attempted using 5-20nM SiGlo as an indicator of positive transfection. Optimisation was 
attempted using conditions recommended by the manufacturer, however cells proved difficult 
to transfect using this method, with transfection efficiency between 2-30% positive cells, 
depending on the conditions used. The reasons for low transfection efficiencies using this 
approach were unclear, and no optimised protocol using the NEON was generated. As an 
alternative, transfections were attempted using the lipofectamine-based RNAiMAX. The 
recommended protocol was followed, however transfection was unsuccessful. Due to time 
constraints an optimised protocol was not developed, and consequently transfection of mir-
200b antagomirs could not be completed. 
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miR-200b expression following transfection with hsa-miR-200b mimic 
miR-200b expression following transfection with negative control#1 
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Figure 15. Successful transient transfection of cell lines with 20nM and 50nM of 
hsa-mir-200b-3p mimic, confirmed by qRT-PCR 
miRNA enriched RNA was extracted from four cell lines, 24 and 48 hours post-
transfection with 20nM of either hsa-mir-200b-3p mirVana mimic (mir-200b mimic) or 
miRNA negative control#1 (control). qRT-PCR was performed to assess miR-200b 
expression post-transfection with mir-200b mimic, relative to matched control cells 
transfected with the control.  (a.) miR-200b expression in cell lines, 24 hours post- 
transfected with 20nM of mir-200b mimic. (b.) miR-200b expression in cell lines, 48 
hours post-transfection with 20nM of mir-200b mimic. (c.) miR-200b expression in cell 
lines, 24 hours post-transfection with 50nM mir-200b mimic.  
 
Expression was normalized against RNU44 as the internal control for D341, PER547, 
and D283, and RNU48 as the internal control for D425. Average cycle threshold values 
(Cts) were included from two independent transfection with three replicates each, with 
Ct values ≥32 being considered as no expression, to eliminate the possibility of 
detecting background noise. The relative quantity of normalised miR-200b expression 
in cells transfected with mir-200b mimic was compared matched control cell line 
transfected with negative control. Transfections successfully restored miR-200b levels 
in all cells transiently transfected with mir-200b mimic. 
 
Change in expression is presented as hsa-mir-200b-3p mimic transfected cells relative 
to the matched miRNA negative control#1 transfected cells (2
-ΔΔCt
).
 
 The error bars 
represent standard deviation between Ct values for each cell line (Ct SD calculated as 
(SD mimic
2
 + SD control
2
)
0.5
).  
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Expression post-transfection with 
hsa-miR-200b-3p mimic 
      DACH1 mRNA expression  
      miR-200b expression 
 
Expression post-transfection with 
miRNA negative control #1 
      DACH1 mRNA expression  
      miR-200b expression 
 
Figure 16. DACH1 mRNA expression is not affected by miR-200b expression in 
cells transiently transfected with 20nM of miR-200b mimic, at 24 hours and 48 
hours post-transfection. 
Cell lines were transfected with 20nM of mir-200b mimic or 20nM of control. Two 
independent transfections were performed, and miRNA-enriched mRNA was extracted 
for analysis at 24 hours and 48 hours post-transfection. Both DACH1 mRNA and miR-
200b expression were assessed in cell lines transfected with miR-200b mimic and 
control, using qRT-PCR. Each qRT-PCR reaction was performed in either duplicate or 
triplicate, and average Ct values were analysed, using GAPDH, RNU44, and RNU48 as 
internal controls. Normalised expression of miR-200b is presented as Log2 transformed 
2
-ΔCt
, and normalised expression of DACH1 is presented as Log2 transformed 2
ΔCt
. 
Error bars represent Ct SD; (Ct SD calculated as (SD mimic
2
 + SD control
2
)
0.5
). 
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Mir-200b expression did increase, however no change in the DACH1 mRNA levels 
was observed at either time point. 
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Figure 17. DACH1 protein expression does not appear to be translationally 
repressed in cells transiently transfected with 20nM of miR-200b mimic, 
compared to cells transfected with 20nM of control, at 24 and 48 hours post-
transfection. 
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Protein lysate was collected from cells transfected with 20nM of mir-200b mimic or 
control, at (a.) 24 hours and (c.) 48 hours post-transfection. Western blot was used to 
detect protein expression and determine if DACH1 protein expression was down-
regulated following restoration of miR-200b expression. Bands were detected at 
97kDa- the expected size of the full length DACH1 protein, and did not appear to show 
reduced intensity in cells transfected with miR-200b mimic compared to cells 
transfected with the control at either time point. β-actin was used as the loading control, 
and showed relatively even loading across all lanes. 
 
Quantitative analysis was then performed for protein expression (b.) 24 hours and (d.) 
48 hours post-transfection, with DACH1 band intensity normalised against β-actin band 
intensity in miR-200b and control-transfected cells, then Log2 transformed. 
Quantitative analysis also did not indicate significantly reduced DACH1 expression at 
either time point.  
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hsa-miR-200b-3p mimic 
      DACH1 mRNA expression  
       miR-200b expression 
Expression post-transfection with 
miRNA negative control #1 
      DACH1 mRNA expression  
      miR-200b expression 
 
Figure 18. DACH1 mRNA expression is not affected by miR-200b in cells 
transiently transfected with 50nM hsa-mir-200b-3p mimic at 24 hours post-
transfection.  
50nM of mimic was transfected into four representative cell lines and miRNA enriched 
RNA was extracted at 24 hours post transfection for expression analysis using qRT-
PCR to determine miR-200b and DACH1 mRNA expression relative to RNU44/48 and 
GAPDH. Two independent experiments were performed, and two to three replicate 
were performed. Ct values from replicates in both experiments were averaged and 
normalised against the appropriate internal control, then Log2 transformed. At this time 
point and this concentration, DACH1 levels remained relatively unchanged in cells 
transfected with mir-200b mimic, compared to those transfected with the control.   
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  DACH1 protein expression in cells transfected with hsa-miR-200b-3p mimic 
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Figure 19. DACH1 protein expression does not appear to be translationally 
repressed in cells transiently transfected with 50nM of miR-200b mimic, 
compared to un-transfected cells, at 24 hours post-transfection 
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(a.) Protein lysate was collected from un-transfected cells (Un-), and cells transfected 
with 50nM of mir-200b mimic 24 hours post-transfection, and used for western blot 
analysis to detect DACH1 protein expression, and assess for any variation in 
expression. A band at approximately 97kDa was detected, and indicates reduced band 
intensity in cells transfected with miR-200b as compared to the un-transfected control. 
β-actin was used as a loading control with relatively even amounts of protein present in 
each lane (b.) For quantitative analysis, the intensity of DACH1 bands were normalised 
against intensity of the internal control β-actin, and then Log2 transformed. 
Quantitative analysis also suggests a reduction in DACH1 at the protein level, in cells 
transiently transfected with mimic. 
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7.0  DISCUSSION 
7.1  DACH1 and miR-200b expression are inversely correlated in medulloblastoma 
cell lines 
DACH1 expression has not previously been specifically investigated in medulloblastoma, but 
previous genome-wide transcriptional profiling indicated elevated expression of DACH1 
relative to normal cerebellum in all four medulloblastoma sub-groups. Notably, DACH1 
expression was significantly higher in Group 4 relative to the other three sub-groups (Mark 
Remke, University of Toronto. Pers comm). DACH1 mutations were not detected in 
medulloblastoma genome sequence analyses (Parsons et al., 2011; Robinson et al., 2012) and 
rarely identified in analyses of other cancers (COSMIC database, COSG74875). This 
suggests a potential oncogenic role of epigenetic up-regulation of DACH1 expression, such 
as by reduced DNA methylation (Hovestadt et al., 2014). Analysis of miRNA expression in a 
small panel of human medulloblastoma specimens performed in the Brain Tumour 
Laboratory at the Telethon Kids Institute, indicated that miR-200b was down-regulated in 
Group 4 medulloblastoma (Genovesi et al., 2011).  Similar to DACH1, reduced expression of 
miR-200b may be a consequence of altered epigenetic mechanisms causing promoter 
hypermethylation affecting miR-200 family cluster and miR-200b, which is frequently down-
regulated in cancer. This reduced expression is associated with early stages of metastasis 
linked to de-regulated EMT (Feng et al., 2014). Here it was predicted that DACH1 was 
regulated by miR-200b and that elevated DACH1 was a result of reduced miR-200b 
expression, potentially associated with the increased metastatic propensity of Group 4 
medulloblastoma. 
 
Additional in silico analysis of the 3’UTR of DACH1 using the TargetScan algorithm 
identified potential binding sites for nine miRNAs/clusters. Of these, the miR-200b/c/429 
cluster was identified as having high probability of binding with a predicted 8-mer binding 
site from nucleotides 971-978 (Figure 10a and 10b). These correlative data are suggestive of 
DACH1 being a target of miR-200b.  To address this possibility in vitro, DACH1 and miR-
200b expression were assessed in six medulloblastoma cell lines. The results demonstrated an 
inverse correlation between DACH1 and miR-200b in these cell lines. Specifically, we 
showed that in cell lines with elevated DACH1, miR-200b was reduced, and vice versa 
(Figure13.). Western blot analysis for DACH1 protein expression in these cell lines was 
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consistent with DACH1 expression at the mRNA level, and was inversely correlated with 
miR-200b expression. This further supported the potential relationship between the 
expression of DACH1 and miR-200b.  
 
The elevated DACH1 expression observed in four of our cell lines representing Group 3 
medulloblastoma is consistent with previous studies that showed a significant increase in 
DACH1 levels in all sub-groups of medulloblastoma, particularly Group 3 and Group 4, 
relative to normal cerebellum. It can be speculated that this elevated expression may be a 
consequence of deregulated epigenetic mechanisms, such as reduced methylation of the 
DACH1 promoter or regulatory elements. This has been suggested previously (Hovestadt et 
al., 2014). Regulation by microRNAs is another possibility, given that there are numerous 
over and under-expressed microRNAs involved in medulloblastoma pathogenesis. Members 
of the miR-200 family in particular are of interest, given their well-described role in 
metastatic cancers (Park et al., 2008; Zhang & Ma, 2012), and putative binding site within the 
DACH1 3’UTR. Tentatively, reduced expression of miR-200b would correspond with the 
metastatic phenotype of Group 4 medulloblastoma (Davalos et al., 2012).  Both DACH1 and 
miR-200b are linked with EMT, through the regulation of the transcription factors Snail and 
ZEB (Barry et al., 2008; K. Wu, Chen, K., Wang, C., et al., 2014), ultimately controlling E-
cadherin expression (Davalos et al., 2012).  
 
It is important to note here that our experiments were carried out using cell lines representing 
Group 3 medulloblastoma, rather than Group 4. However, it is evident that some Group 3 
tumours expressed higher levels of DACH1. Additionally, an association was still seen 
between DACH1 and miR-200b levels. This suggests that a potential relationship between 
DACH1 and miR-200b also exists in Group 3 medulloblastoma, however, there may be 
underlying differences in the mechanisms associated with altered expression 
 
To our knowledge, DACH1 has not yet been verified as a target of miR-200b in any context. 
Here, we speculate that in medulloblastoma, DACH1 is a target of miR-200b, and that 
reduced miR-200b results in elevated DACH1, and this may be linked to Group 4 
medulloblastoma pathogenesis. This warranted further investigation to determine whether 
DACH1 is a bona-fide target of miR-200b.  
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7.2 Stable lentiviral transduction to generate reporter cell lines 
To address whether DACH1 is a bona fide target of miR-200b, we attempted to transduce our 
medulloblastoma cell lines with a DACH1-3’UTR-GFP-Lenti reporter virus, to confirm 
direct targeting by miR-200b. However, issues with contamination of commercial viral stocks 
prevented these experiments from being carried out. Initially, the high amount of cell death 
observed following transduction was assumed to be due to poor transduction efficiency, 
resulting in low numbers of puromycin resistant cells. Optimisation experiments were carried 
out using different viral MOIs and longer recovery times following transduction, in attempt to 
improve cell viability. It was observed that cell death was occurring prior to puromycin 
selection. Bacterial contamination was suspected given that both the untransduced control 
cells, and positive controls containing a GFP control lentivirus generated within out lab, 
showed no evidence of contamination and the source was traced to the viral stocks. To 
confirm, all components/reagents used for transductions, including fresh vials of virus, were 
inoculated into medium and incubated at 37
o
C for 72-96 hours. Bacterial outgrowth was 
detected only where viral media was inoculated, confirming contamination of viral stocks 
purchased from a commercial source.  
 
Subsequently, we generated our own lenti-reporter virus containing DACH1-3’UTR-
Luciferase-plasmid purchased from ABM. Inc. (the same supplier of the original viruses). 
Our lentivirus successfully transduced DAOY cells and generated puromycin resistant 
colonies. However, transduction of semi-adherent medulloblastoma cell lines was 
unsuccessful. The reasons for this were unclear, and further experiments were abandoned due 
to time constraints. Possible explanations include a low viral MOI, not sufficient for 
transducing cells; the slower proliferation rates of the semi-adherent cell lines, or the 
tendency for these cells to aggregate reducing surface area available for viral transduction. 
For future investigation/experiments, an alternative optimised protocol is required. 
 
7.3 Transient transfection to alter miR-200b levels  
In the meantime, an alternative approach was used to investigate whether restoring miR-200b 
expression had any effect on DACH1 mRNA/protein expression. Cells with low levels of 
miR-200b expression were transiently transfected with a single hsa-miR-200b-3p mimic to 
restore miR-200b levels, followed by analysis of DACH1 mRNA and protein expression. 
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Two concentrations (20nM and 50nM) of hsa-miR-200b-3p mimic (miR-200b mimic) and 
miRNA negative control#1 (control) were selected, and post-transfection analysis was 
performed 24 and 48 hours post-transfection. Transfection efficiency was confirmed based on 
an increase in detectable mir-200b mimic compared to cells transfected with the control. 
Although transfection of mir-200bmimic successfully increased miR-200b to detectable 
levels, post-transfection analysis of DACH1 mRNA did not reveal any noticeable difference 
in expression at either time point. However, given that translation repression may occur even 
when mRNA remains stable (Djuranovic, Nahvi, & Green, 2012; Selbach, Schwanhausser, & 
Thierfelder, 2008), DACH1 protein was assessed by western blot, to determine if translation 
repression was evident. At both 24 and 48 hours post transfection, with 20nM of 
mimic/control, no decrease in DACH1 protein was detected. Using 50nM of mimic, there 
was some indication of protein repression in mimic-transfected cells compared to un-
transfected cells, as determined by visual analysis. Unfortunately, no repeat experiment was 
performed for confirmation due to time constraints. 
 
Others have demonstrated successful inhibition of target following transfection of miR-200b 
mimics (Hailin et al., 2013; Ye et al., 2014), however we were unable to show down-
regulation of DACH1 following transfection with a mir-200b mimic. This is suggestive that 
miR-200b is not capable of regulating DACH1 expression, however it would be premature to 
make this assumption without additional experiments.  
 
Reporter screening would be ideal, and would provide a more conclusive indication of any 
potential interaction (Thomson, Bracken, & Goodall, 2011).  Such experiments would 
involve the development of reporter cell lines, and assessing reporter activity relative to the 
amount of miR-200b expressed. Subsequently assessing reporter expression after transfection 
of mir-200b mimics and antagomirs would provide evidence of miR-200b directly interacting 
with the putative target within the DACH1 3’UTR. Furthermore, generating lentiviruses with 
mutations to the putative binding site, and assessing changes in reporter expression, in a 
similar fashion as described above, would provide direct evidence of whether miR-200b 
targets the DACH1 3’UTR directly. Evidence of miR-200b binding to the DACH1 3’UTR 
could then be confirmed by transfection of mimics and assessment by qRT-PCR and western 
blot, similar to what is described here.  
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In addition, regarding experimental design, which involved only two time points (24 and 48 
hours), it is possible that any detectable changes occurred outside of this range. A broader 
range, with earlier time points (6-12 hours) and later time points (72 hours), would allow a 
more comprehensive assessment of any potential changes in DACH1 expression. In the long-
term, this could be enhanced by the use of a lentiviral vector to stably maintain up regulation 
of miR-200b. Similarly, the amount of mimic used may need to be adjusted for any effects to 
be observed.  
 
It is also acknowledged that assessing only one microRNA, miR-200b, may be a limited 
approach. It is likely that the regulation of DACH1 is more complex, involving additional 
miRNAs, particularly those of the miR-200 family sharing the same seed sequence (miR-
200c, and miR429). Including additional members of the miR-200 family, both individually 
and in combination, would be an ideal approach.  
 
Another possibility is that there may be alterations within the 3’UTR that abrogate miR-200b 
binding. Although this was not investigated here, it has been previously demonstrated that 
during oncogenic transformation, a gene’s 3’UTR may become truncated or elongated, 
enabling a gene to escape miRNA regulation (L. Li et al., 2014; Lianoglou, Garg, Yang, 
Leslie, & Mayr, 2013). As the mRNA sequence of DACH1 in our cell lines was not 
examined, this would be an interesting concept for further investigation. 
 
7.4 TaqMan qRT-PCR assays  
The small nucleolar-RNAs (snoRNAs); RNU44 and RNU48, which were selected as internal 
controls, are commonly used for assessing miRNA expression, however do show variation in 
expression in different cancer types (Gee et al., 2011). In this study, some discrepancies in 
the efficiency of the RNU44 and RNU48 primers were observed, and this introduces some 
bias. Notably different Ct values for RNU44 were detected between D425 and the other cell 
lines. Subsequently, RNU48 was assessed as a control to be used in D425, and demonstrated 
similar efficiency to RNU44.   
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In subsequent post-transfection experiments, variation in RNU44/RNU48 expression was 
observed across all samples, which hints at a change induced by the transfection process or 
by miR-200b. Such variation was not expected when these internal control were selected, as 
previous analysis has demonstrated their validity (Genovesi, Anderson, Carter, Giles, & 
Dallas, 2012). Additionally, experimental error may be a factor, due to inexperience with the 
technique, or potentially the transfections themselves affect RNU44/RNU48 expression. 
Taking these possibilities into consideration, a range of potential internal controls should be 
assessed to reduce this variation.  
 
Considering the consistent variation in internal control expression between cells that were 
transfected with mir-200b compared to those transfected the control, data was simply 
presented as 2
-ΔCt
 (i.e. expression respective to control) and Log2 transformed, to avoid 
potential bias. 
 
7.5 Additional considerations 
Although here it is proposed that DACH1 and miR-200b may be involved in Group 4 
medulloblastoma pathogenesis, we were only able to test this association in Group 3 
medulloblastoma cell lines. However, DACH1 up-regulation was detected in all 
medulloblastoma subgroups relative to normal cerebellum, suggesting that DACH1 
overexpression may be relevant to medulloblastoma more generally. Taking this into 
consideration, it is possible that any association between DACH1 and miR-200b in 
medulloblastoma pathogenesis is not exclusive to Group 4. Indeed, we observed the inverse 
correlation in most of the cell lines including those of the SHH subgroup. Additionally, the 
roles of DACH1 and miR-200b in EMT raise the possibility that this putative association is 
relevant across all metastatic medulloblastoma, not just in Group 4.  
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8.0  CONCLUSION  
The regulation of DACH1 by miR-200b remains to be definitively demonstrated. Although 
our findings were not suggestive of regulation at either the mRNA or protein level, initial 
correlative evidence would suggest an association. Additionally, our approach to assessing 
the functional relationship between DACH1 and miR-200b was limited due to both time 
constraints and issues with contaminated lentivirus requiring an alternative experimental 
approach. Considering all possibilities addressed above, the regulation of DACH1 is likely to 
be more complex, and probably involves additional microRNAs, particularly those of the 
miR-200 family with identical seed sequences to miR-200b (mir-200c and miR-429). If miR-
200b does target DACH1, it may only produce a subtle change.  
 
Cell lines stably transduced to express miR-200b could be used for long-term assessment of 
the effects of miR-200b not only on DACH1, but also the effects on cell phenotype, and 
particularly cell migration. Finally, although ambitious at this point, the development of 
mouse models engineered to over-express DACH1 and/or under-express miR-200b could 
potentially provide valuable understanding into the mechanisms of medulloblastoma 
pathogenesis.  
 
Finally, although the role of DACH1 as an oncogene in medulloblastoma, remains to be 
conclusively demonstrated, the available data suggest that further characterisation of the role 
of DACH1 in medulloblastoma pathogenesis is warranted.  
 
 
 
 
 
 
 
 
73 
 
9.0     REFERENCES   
 
Atkins, M., Jiang, Y., Sansores-Garcia, L., Jusiak, B., Halder, G., & Mardon, G. (2013). 
Dynamic rewiring of the Drosophila retinal determination network switches its 
function from selector to differentiation. PLoS genetics, 9(8).   
Bai, A. H. C., Bazhin, A. V., Eichmüller, S. B., Kulozik, A. E., Pscherer, A., Benner, A., . . . 
Jugold, M. (2012). MicroRNA-182 promotes leptomeningeal spread of non-sonic 
hedgehog-medulloblastoma. Acta Neuropathologica, 123(4), 529-538.   
Barry, S. C., Bert, A. G., Farshid, G., Goodall, G. J., Gregory, P. A., Khew-Goodall, Y., . . . 
Vadas, M. A. (2008). The miR-200 family and miR-205 regulate epithelial to 
mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10.   
Cho, W. C. S. (2007). OncomiRs: the discovery and progress of microRNAs in cancers. 
Molecular cancer, 6(1), 60-60.   
Cottonham, C. L., Kaneko, S., & Xu, L. (2010). miR-21 and miR-31 converge on TIAM1 to 
regulate migration and invasion of colon carcinoma cells. The Journal of biological 
chemistry, 285(46), 35293-35302.   
D'Amato, N. C., Howe, E. N., & Richer, J. K. (2013). MicroRNA regulation of epithelial 
plasticity in cancer. Cancer letters, 341(1), 46.   
Davalos, V., Moutinho, C., Villanueva, A., Boque, R., Silva, P., Carneiro, F., & Esteller, M. 
(2012). Dynamic epigenetic regulation of the microRNA-200 family mediates 
epithelial and mesenchymal transitions in human tumorigenesis. Oncogene, 31(16), 
2062-2074.   
Davis, R. J., Mardon, G., Shen, W., Sandler, Y. I., Amoui, M., Purcell, P., . . . Beaudet, A. L. 
(2001). Dach1 mutant mice bear no gross abnormalities in eye, limb, and brain 
development and exhibit postnatal lethality. Molecular and cellular biology, 21(5), 
1484-1490.   
Davis, R. J., Shen, W., Heanue, T. A., & Mardon, G. (1999). Mouse Dach, a homologue of 
Drosophila dachshund, is expressed in the developing retina, brain and limbs. 
Development genes and evolution, 209(9), 526-536.   
Davis, R. J., Shen, W., Sandler, Y. I., Heanue, T. A., & Mardon, G. (2001). Characterization 
of mouse Dach2, a homologue of Drosophila dachshund. Mechanisms of 
Development, 102(1-2), 169-179.   
74 
 
Desmond, G. P., Gopal Krishna, R. D., Christophe, L., Tony, A., Hany, O. H., Ian, O. E., . . . 
Graham, R. B. (2014). DACH1: Its Role as a Classifier of Long Term Good Prognosis 
in Luminal Breast Cancer: e84428. PLoS One 9(1).  
DeSouza, R.-M., Jones, B. R. T., Lowis, S. P., & Kurian, K. M. (2014). Pediatric 
medulloblastoma - update on molecular classification driving targeted therapies. 
Frontiers in oncology, 4, 176.   
Ding, X.-M. (2014). MicroRNAs: regulators of cancer metastasis and epithelial-
mesenchymal transition (EMT). Chinese journal of cancer, 33(3), 140-147.   
Djuranovic, S., Nahvi, A., & Green, R. (2012). miRNA-mediated gene silencing by 
translational repression followed by mRNA deadenylation and decay. Science (New 
York, N.Y.), 336(6078), 237.   
Doench, J. G., & Sharp, P. A. (2004). Specificity of microRNA target selection in 
translational repression. Genes & development, 18(5), 504-511.   
Dubuc, A. M., Morrissy, A. S., Shih, D., Peacock, J., Ramaswamy, V., Rolider, A., . . . 
Unterberger, A. (2013). Aberrant patterns of H3K4 and H3K27 histone lysine 
methylation occur across subgroups in medulloblastoma. Acta neuropathologica, 
125(3), 373-384.   
Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs - microRNAs with a role in cancer. 
Nature Reviews Cancer, 6(4), 259-269.   
Fabbri, M., Croce, C. M., & Calin, G. A. (2008). MicroRNAs. Cancer journal, 14(1), 1-6.  
Feng, X., Wang, Z., Fillmore, R., & Xi, Y. (2014). MiR-200, a new star miRNA in human 
cancer. Cancer letters, 344(2), 166.  
Ferretti, E., Farcomeni, A., Nofroni, I., Laneve, P., Gioia, U., Caffarelli, E., . . . Giangaspero, 
F. (2009). MicroRNA profiling in human medulloblastoma. International journal of 
cancer, 124(3), 568-577.  
Finnegan, E. F., & Pasquinelli, A. E. (2013). MicroRNA biogenesis: regulating the 
regulators. Critical Reviews in Biochemistry and Molecular Biology, 48(1), 51-68.  
Firiedman, H. S., et al., . (1988). Phenotypic and genotypic analysis od a human 
medulloblastoma cell line and transplantable xenografy (D341Med) demonstrating 
amplification of c-myc. The American Journal of Pathology, 130(3).   
Friedman, H. S., et al.,. (1985). Establishment and characterization of the human 
medulloblastoma cell line and transplatable xenograft D283 Medulloblastoma. 
Journal of neuropathology and experimental neurology, 44(6).   
75 
 
Gee, H. E., Buffa, F. M., Camps, C., Ramachandran, A., Leek, R., Taylor, M., . . . Harris, A. 
L. (2011). The small-nucleolar RNAs commonly used for microRNA normalisation 
correlate with tumour pathology and prognosis. Br J Cancer, 104(7), 1168-1177.   
Genovesi, L. A., Anderson, D., Carter, K. W., Giles, K. M., & Dallas, P. B. (2012). 
Identification of suitable endogenous control genes for microRNA expression 
profiling of childhood medulloblastoma and human neural stem cells. BMC research 
notes, 5(1), 507-507.   
Genovesi, L. A., Carter, K. W., Gottardo, N. G., Giles, K. M., & Dallas, P. B. (2011). 
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma 
compared with neural stem cells. PloS One, 6(9), e23935.   
Gerber, N. U., Mynarek, M., Von Hoff, K., Friedrich, C., Resch, A., & Rutkowski, S. (2014). 
Recent developments and current concepts in medulloblastoma. Cancer Treatment 
Reviews, 40(3), 356-365.   
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., . . . 
Gilbertson, R. J. (2010). Subtypes of medulloblastoma have distinct developmental 
origins. Nature, 468(7327), 1095-1099.   
Hailin, T., Min, D., Yunyun, T., Xinhua, X., Jiaoli, G., Yanan, K., . . . . (2013). miR-200b 
and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell 
Progression. Clinical Cancer Research, 19(20).   
He, X. M., et al.,. (1991). Differentiation characteristics of newly established 
medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their 
transplantable xenografts. Laboratory investigation; a journal of technical methods 
and pathology, 64(6).  
Holthouse, D. J., Dallas, P. B., Ford, J., Fabian, V., Murch, A. R., Watson, M., . . . Kees, U. 
(2008). Classic and desmoplastic medulloblastoma: complete case reports and 
characterizations if two new cell lines. Neuropathology, 29(4).   
Hovestadt, V., Warnatz, H.-J., Ralser, M., Brun, S., Bunt, J., Jäger, N., . . . Ryzhova, M. 
(2014). Decoding the regulatory landscape of medulloblastoma using DNA 
methylation sequencing. Nature, 510(7506), 537.   
Huang, Y., Yang, Y. B., Zhang, X. H., Yu, X. L., Wang, Z. B., & Cheng, X. C. (2013). 
MicroRNA-21 gene and cancer. Medical oncology 30(1), 376-379.   
Huse, J. T., & Holland, E. C. (2010). Targeting brain cancer: advances in the molecular 
pathology of malignant glioma and medulloblastoma. Nature reviews Cancer, 10(5), 
319-331.   
76 
 
Jacobsen, P. F., Jenken, D.J., Papadimitriou, J.M. . (1985). Establishment of a human 
medulloblastoma cell line and its heterotransplantation into nude mice. Journal of 
neuropathology and experimental neurology, 44(5), 472-485.   
Jones, D. T. W., Northcott, P. A., Kool, M., & Pfister, S. M. (2013). The role of chromatin 
remodeling in medulloblastoma. Brain pathology, 23(2), 193-199.   
Jones, D. T. W., Stütz, A. M., Rausch, T., Warnatz, H.-J., Ryzhova, M., Bender, S., . . . 
Lichter, P. (2012). Dissecting the genomic complexity underlying medulloblastoma. 
Nature, 488(7409), 100-105.   
Keles, G. E., et as.,. (1991). Establishment and characterisation of four human 
medulloblastoma-derived cell lines. Oncology Research, 7(10-11).   
Klesse, L. J., & Bowers, D. C. (2010). Childhood Medulloblastoma: Current Status of 
Biology and Treatment (Vol. 24, pp. 285-301). Cham: Adis International. 
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012). microRNAs in 
cancer management. The Lancet. Oncology, 13(6), e249-e258.   
Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial-
mesenchymal transition and cancer cell migration by direct targeting of E-cadherin 
transcriptional repressors ZEB1 and ZEB2. The Journal of Biological Chemistry, 
283(22), 14910-14914.   
Korshunov, A., Ryzhova, M., Cho, Y.-J., Wittmann, A., Benner, A., Weiss, W. A., . . . Jones, 
D. T. W. (2012). Biological and clinical heterogeneity of MYCN-amplified 
medulloblastoma. Acta Neuropathologica, 123(4), 515-527.   
Lau, J., Schmidt, C., Markant, S. L., Taylor, M. D., Wechsler-Reya, R. J., & Weiss, W. A. 
(2012). Matching mice to malignancy: molecular subgroups and models of 
medulloblastoma. Child's nervous system: official journal of the International Society 
for Pediatric Neurosurgery, 28(4), 521-532.  
Lee, J. W., Kim, H. S., Kim, S., Hwang, J., Kim, Y. H., Lim, G. Y., . . . Lee, S. (2012). 
DACH1 regulates cell cycle progression of myeloid cells through the control of cyclin 
D, Cdk 4/6 and p21Cip1. Biochemical and Biophysical Research Communications, 
420(1), 91-95.  
Li, K. K. W., Lau, K. M., & Ng, H. K. (2013). Signaling pathway and molecular subgroups 
of medulloblastoma. International journal of clinical and experimental pathology 
6(7), 1211.   
77 
 
Li, L., Wang, D., Xue, M., Mi, X., Liang, Y., & Wang, P. (2014). 3' UTR shortening 
identifies high-risk cancers with targeted dysregulation of the ceRNA network. 
Scientific Reports, 4.   
Liang, F., Lu, Q., Sun, S., Zhou, J., Popov, V. M., Li, S., . . . Kong, B. (2012). Increased 
expression of dachshund homolog 1 in ovarian cancer as a predictor for poor 
outcome. Int J Gynecol Cancer, 22(3), 386-393.   
Lianoglou, S., Garg, V., Yang, J. L., Leslie, C. S., & Mayr, C. (2013). Ubiquitously 
transcribed genes use alternative polyadenylation to achieve tissue-specific 
expression. Genes & development, 27(21), 2380.   
Lindsey, J. C., Anderton, J. A., Lusher, M. E., & Clifford, S. C. (2005). Epigenetic events in 
medulloblastoma development. Neurosurgery Focus, 19(5), E10.   
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data Using 
Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods, 25(4), 402-408.  
Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., . . . Weinberg, R. A. (2010). 
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer 
metastasis. Nature Cell Biology, 12(3), 247-256.   
MacDonald, T. J., Aguilera, D., & Castellino, R. C. (2014). The rationale for targeted 
therapies in medulloblastoma. Neuro-oncology, 16(1), 9-20.   
Mardon, G., Solomon, N. M., & Rubin, G. M. (1994). dachshund encodes a nuclear protein 
required for normal eye and leg development in Drosophila. Development, 120(12), 
3473-3486.   
Men, D., Liang, Y., & Chen, L. (2014). Decreased expression of microRNA-200b is an 
independent unfavorable prognostic factor for glioma patients. Cancer epidemiology 
38(2), 152.   
Min, H. S., Lee, J. Y., Kim, S.-K., & Park, S.-H. (2013). Genetic grouping of 
medulloblastomas by representative markers in pathologic diagnosis. Translational 
Oncology 6(3), 265.   
Nguyen, D. X., & Massagué, J. (2007). Genetic determinants of cancer metastasis. Nature 
Reviews Genetics, 8(5), 341-352.   
Northcott, P. A., Korshunov, A., Pfister, S. M., & Taylor, M. D. (2012). The clinical 
implications of medulloblastoma subgroups. Nature reviews Neurology, 8(6), 340.  
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., . . . 
Taylor, M. D. (2011). Medulloblastoma comprises four distinct molecular variants. 
Journal Of Clinical Oncology, 29(11), 1408-1414.  
78 
 
Northcott, P. A., Schumacher, S. E., Rubin, J. B., Beroukhim, R., Ellison, D. W., Marshall, 
C. R., . . . Leonard, J. R. (2012). Subgroup-specific structural variation across 1,000 
medulloblastoma genomes. Nature, 488(7409), 49-56.   
Northcott, P. A., Taylor, M. D., Pfister, S. M., Jones, D. T. W., Kool, M., Robinson, G. W., . . 
. Lichter, P. (2012). Medulloblastomics: the end of the beginning. Nature reviews 
Cancer, 12(12), 818-834.   
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines 
the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 
and ZEB2. Genes & development, 22(7), 894-907.   
Parsons, D. W., Bettegowda, C., Gallia, G. L., Jallo, G. I., Binder, Z. A., Nikolsky, Y., . . . 
Samayoa, J. (2011). The Genetic Landscape of the Childhood Cancer 
Medulloblastoma. Science, 331(6016), 435-439.   
Pizer, B., & Clifford, S. (2008). Medulloblastoma: new insights into biology and treatment. 
Archives of disease in childhood. Education and practice edition, 93(5), 137-144.   
Pöschl, J., Kool, M., Schüller, U., Stark, S., Neumann, P., Gröbner, S., . . . Pfister, S. M. 
(2014). Genomic and transcriptomic analyses match medulloblastoma mouse models 
to their human counterparts. Acta neuropathologica, 128(1), 123-136.  
Remke, M., Ramaswamy, V., & Taylor, M. D. (2013). Medulloblastoma molecular 
dissection: the way toward targeted therapy. Current Opinion In Oncology, 25(6), 
674-681.   
Robinson, G., Zhu, X., Chalhoub, N., Baker, S. J., Huether, R., Kriwacki, R., . . . Wei, L. 
(2012). Novel mutations target distinct subgroups of medulloblastoma. Nature, 
488(7409), 43-48.   
Roussel, M. F., & Robinson, G. W. (2013). Role of MYC in Medulloblastoma. Cold Spring 
Harbor Perspectives In Medicine, 3(11). 
Schmittgen, T. D., & Livak, K. J. (2008). Analyzing real-time PCR data by the comparative 
CT method. Nat. Protocols, 3(6), 1101-1108.   
Schroeder, K., & Gururangan, S. (2014). Molecular variants and mutations in 
medulloblastoma. Pharmacogenomics and Personalized Medicine, 7, 43-51.   
Selbach, M., Schwanhausser, B., & Thierfelder, N. (2008). Widespread changes in protein 
synthesis induced by microRNAs. Nature 455, 58.   
Silber, J., Hashizume, R., Felix, T., Hariono, S., Yu, M., Berger, M. S., . . . Gupta, N. (2013). 
Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro-Oncology, 
15(1), 83-90.   
79 
 
Sunde, J., Donninger, H., Wu, K., Johnson, M., Pestell, R., Rose, G., . . . Birrer, M. (2006). 
Expression profiling identifies altered expression of genes that contribute to the 
inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res, 
66(17), 8404 - 8412.   
Swartling, F. J., Yakovenko, S., Zhe, X.-N., Gilmer, H. C. F., Collins, R., Nagaoka, M., . . . 
Cancer och, v. (2010). Pleiotropic role for MYCN in medulloblastoma. Genes & 
development, 24(10), 1059-1072.   
Tavsanli, B. C., Ostrin, E. J., Burgess, H. K., Middlebrooks, B. W., Pham, T. A., & Mardon, 
G. (2004). Structure–function analysis of the Drosophila retinal determination protein 
Dachshund. Developmental Biology, 272(1), 231-247.   
Taylor, M. D., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., . . . 
Rutkowski, S. (2012). Molecular subgroups of medulloblastoma: the current 
consensus. Acta Neuropathologica, 123(4), 465-472.   
Thomson, D. W., Bracken, C. P., & Goodall, G. J. (2011). Experimental strategies for 
microRNA target identification. Nucleic acids research, 39(16), 6845-6853.   
Uziel, T., Hannon, G., Roussel, M. F., Karginov, F. V., Xie, S., Parker, J. S., . . . Gilbertson, 
R. J. (2009). The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway 
in medulloblastoma. Proceedings of the National Academy of Sciences 106(8), 2812-
2817.   
Vonlanthen, J., Marra, G., Okoniewski, M. J., Menigatti, M., Cattaneo, E., Pellegrini-
Ochsner, D., . . . Buffoli, F. (2014). A comprehensive look at transcription factor gene 
expression changes in colorectal adenomas. BMC cancer, 14(1). 
Weeraratne, S. D., Bai, A. H. C., Warren, P., Pfister, S. M., Steen, J. A. J., Pomeroy, S. L., . . 
. Remke, M. (2012). Pleiotropic effects of miR-183~96~182 converge to regulate cell 
survival, proliferation and migration in medulloblastoma. Acta Neuropathologica, 
123(4), 539-552.  
Williams, L. V., Veliceasa, D., Vinokour, E., & Volpert, O. V. (2013a). miR-200b inhibits 
prostate cancer EMT, growth and metastasis. PloS one 8(12).   
Williams, L. V., Veliceasa, D., Vinokour, E., & Volpert, O. V. (2013b). miR-200b inhibits 
prostate cancer EMT, growth and metastasis. PloS one 8(12)  
Wlodarski, P. K., & Jozwiak, J. (2008). Therapeutic targets for medulloblastoma. Expert 
Opinion on Therapeutic Targets, 12(4), 449-461. 
80 
 
Wu, K., Chen, K., Wang, C.,, Jiao, X., Wang, L., Zhou, J., Wang, J., Li, Z., . . . Pestell, R. G. 
(2014). Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and 
translation. Cancer Research, 74(3), 829-839.   
Wu, K., Pestell, R. G., Katiyar, S., Li, A., Liu, M., Ju, X., . . . Casola, A. (2008). Dachshund 
inhibits oncogene-induced breast cancer cellular migration and invasion through 
suppression of interleukin-8. Proceedings of the National Academy of Sciences of the 
United States of America, 105(19), 6924-6929.   
Wu, K., Pestell, R. G., Liu, M., Li, A., Donninger, H., Rao, M., . . . Birrer, M. (2007). Cell 
fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. 
Molecular Biology of the cell, 18(3), 755-767.   
Wu, K., Sauter, G., Russell, R. G., Cvekl, A., Pestell, R. G., Li, A., . . . Lisanti, M. P. (2006). 
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor 
growth. Molecular and Cellular Biology, 26(19), 7116-7129.   
Wu, L., Li, W., Guo, M., Herman, J. G., Brock, M. V., Wu, K., . . . Zhan, Q. (2014). 
Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-[beta] 
signaling. PLoS ONE, 9(4).   
Wu, L., Li, W., Guo, M., Herman, J. G., Brock, M. V., Wu, K., . . . Zhan, Q. (2014). 
Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling. 
PloS one 9(4). 
Xu, Q.-F., Pan, Y.-W., Li, L.-C., Zhou, Z., Huang, Q.-L., Pang, J. C.-S., . . . Lv, S.-Q. (2014). 
MiR-22 is Frequently Down-regulated in Medulloblastomas, and Inhibits Cell 
Proliferation via the Novel Target PAPST1. Brain Pathology.   
Yan, W., Wu, K., Herman, J. G., Brock, M. V., Fuks, F., Yang, L., . . . Guo, M. (2013). 
Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal 
cancer. Epigenetics, 8(12), 1373-1383.   
Yan, W., Wu, K., Herman, J. G., Brock, M. V., Zhou, Y., Lu, Y., . . . Guo, M. (2014). 
Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer 
by activating TGF-β signalling. Journal of Cellular and Molecular Medicine.   
Ye, F., Tang, H., Liu, Q., Xie, X., Wu, M., Liu, X., . . . Xie, X. (2014). miR-200b as a 
prognostic factor in breast cancer targets multiple members of RAB family. Journal 
of translational medicine, 12(1), 17-17.   
Zhang, J., & Ma, L. (2012). MicroRNA control of epithelial-mesenchymal transition and 
metastasis. Cancer metastasis reviews, 31(3-4), 653-662.   
81 
 
Zhou, J., Tozeren, A., Zhao, K., Lisanti, M. p., Pestell, R. G., Wang. Chenguang., . . . Quong, 
A. (2010). Attenuation of Forkhead signaling by the retinal determination factor 
DACH1. Proceedings of the National Academy of Sciences of the United States of 
America, 107(15), 6864-6869.   
Zhu, H., Guo, M., Wu, K., Yan, W., Hu, L., Yuan, J., . . . Yang, Y. (2013). Epigenetic 
silencing of DACH1 induces loss of transforming growth factor-β1 antiproliferative 
response in human hepatocellular carcinoma. Hepatology (Baltimore, Md.), 58(6), 
2012-2022.  
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008). MicroRNA-21 targets 
tumor suppressor genes in invasion and metastasis. Cell Research, 18(3), 350-359. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
VII.  
APPENDICES 
Appendix A. Ethics approval declaration 
Project Number: 11288 GEORGE 
Project Name: The role of Dachshund Homolog 1 and the miR-200 family in 
medulloblastoma pathogenesis 
 
Student Number: 10145031 
  
 The ECU Human Research Ethics Committee (HREC) has reviewed your application and 
has granted ethics approval for your research project. In granting approval, the HREC has 
determined that the research project meets the requirements of the National Statement on 
Ethical Conduct in Human Research. 
  
The approval period is from 16 May 2014 to 30 November 2014. 
 
Appendix B. qRT-PCR data 
Abbreviations 
Cycle Threshold Ct 
Standard Deviation SD 
ΔCt Normalised expression (Average Ct target – Average Ct internal control 
ΔΔCt Relative expression (ΔCt test – ΔCt control) 
Relative Quantitation RQ 
 
qRT-PCR analysis of miR-200b in medulloblastoma cell lines  
 
1 1 1 2 2 2 3 3 3 Average Ct SD Ct SD ΔCt ΔΔCt 2^-ΔΔCt Log2 RQ 
Daoy 
                miR-200b 29.33775 28.23541 27.96166 30.9249 30.3264 
 
32.2878 30.77175 30.59115 30.054603 1.3612675 2.3718901 4.120265 -6.409015 84.977886 6.4090156 
RNU44 27.03735 26.04543 25.43368 28.95017 28.47356 
 
24.04086 23.79317 23.70048 25.934338 1.9423731 
     
                 UW228 
                miR-200b 35 32.94062 32.02717 32.1551 31.09239 
 
29.41409 29.85187 
 
31.783034 1.7608922 1.8990813 7.1926971 -3.336583 10.102101 3.3365834 
RNU44 25.649 24.34473 23.63739 25.61797 24.38796 
 
24.00339 24.49192 
 
24.590337 0.7111738 
     PER547 
                
miR-200b 33.91859 33.03051 30.31595 36.436893 35.600822 30.62758 
33.23739 
34.47557 32.23739 33.28951 1.7537825 2.1293431 10.873032 0.3437517 0.7879895 -0.343751 
RNU44 22.26352 21.78283 20.87944 22.123 22.156 20.60696 24.46166 23.82999 23.6449 22.416478 1.243004 
     D283 
                miR-200b 30.94545 30.12548 29.63841 34.11824 34.42992 33.86202 34.3392 33.8964 33.373714 32.747648 1.8253176 2.736219 10.529281 0 1 0 
RNU44 25.96366 24.92622 23.86636 21.62347 20.97276 20.27967 21.67582 20.66049 19.996859 22.218368 2.0384087 
     D341 
                miR-200b 32.149 31.39827 30.14953 33.91484 33.7179 33.73136 34.83827 33.5502 
 
33.328549 1.075924 1.7216024 10.832944 0.3036637 0.8101923 -0.303663 
RNU44 24.77855 23.96069 22.82445 21.66571 20.61304 20.42971 21.72953 21.89726 
 
22.495604 1.3439874 
     D425 
                
miR-200b 32.95625 31.9533 33.25469 
36.90059 
31.45496 
36.55563 
   
33.269867 1.3609153 1.7390875 9.667665 -0.861615 1.817072 0.8616156 
RNU48 24.50856 24.71615 24.80508 22.45871 22.39714 22.72757 
   
23.602202 1.0827442 
      
 
 
 
 
 
 
 qRT-PCR analysis of miR-200b expression in cell lines, 24 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to RNU44/RNU48 
 
1 1 1 2 2 2 Average SD Ct SD ΔCt 2^-ΔCt Log2 RQ 
D341 mimic             
200b 21.52807 21.48088 21.3638 24.9736 24.36937 24.28898 23.000792 1.55902 1.90097 -1.0367 2.05151 1.03668 
RNU44 25.27176 25.13319 24.9591 22.9666 22.92638 22.96787 24.037475 1.08772         
D341 control                         
200b 33.31676 32.99001 32.6836 34.3684 34.5461 33.86804 33.628817 0.68854 1.74598 9.33364 0.00155 -9.3336 
RNU44 25.85066 25.87212 25.9705 22.8274 22.649 22.60136 24.295182 1.60448         
D425 mimic                         
200b 22.76947 22.83269 22.8315 23.6105 23.57149 23.47665 23.182048 0.34584 0.4596 -2.0928 4.26572 2.09279 
RNU48 24.97602 24.97247 24.9687 25.5533 25.59148 25.58709 25.274838 0.3027         
D425 control                         
200b 32.67465 31.51094 32.6603 35.0083 35.07362   33.385556 1.41623 1.41769 8.37001 0.00302 -8.37 
RNU48 24.9633 25.08756 24.9324 25.0912 25.00321 24.99139 25.01555 0.06435         
PER547 mimic                         
200b 21.57425 21.50414 21.4114 23.2451 23.20869 23.04483 22.331403 0.8384 1.68396 -1.6292 3.09342 1.6292 
RNU44 25.53641 25.45538 25.2642 22.4639 22.52344 22.52037 23.960605 1.46041         
PER547                         
200b 36.95118 36.41425 36.6832 36.9732 35.55816 35.30413 36.314012 0.65549 0.99237 11.6624 0.00031 -11.662 
RNU44 25.4038 25.36094 25.4203 24.0012 23.86684 23.85657 24.651612 0.74507         
D283 mimic                         
200b 22.22203 22.17984 22.1515 23.0709 23.03091 22.90829 22.531016 0.42525 1.34479 -1.844 3.59014 1.84404 
RNU44 25.41844 25.40425 25.4272 22.8376 22.78781   24.375056 1.27578         
D283 control                         
200b 32.9179 33.74686 33.7841 35.1563 35.45034 34.59473 34.275028 0.87768 1.52129 9.28157 0.00161 -9.2816 
RNU44 26.26553 26.256 26.1745 23.9212 23.75376 23.58982 24.99346 1.24257         
 
 
 
 
 
 
qRT-PCR analysis of miR-200b expression in cell lines, 48 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to RNU44/RNU48 
 
1 1 1 2 2 2 Average SD Ct SD ΔCt 2^-ΔCt Log2 RQ 
D341 mimic             
200b 24.552967 23.854042 23.599588 24.972551 24.921453 24.914639 24.46920667 0.547413953 0.574 2.705776333 0.153278119 -2.705776333 
RNU44 21.538748 21.803959 21.522717 21.888258 21.977558 21.849342 21.76343033 0.172665887         
D341 control 
      
            
200b 34.174767 36.919975 33.07282 34.115894 33.657753 33.456047 33.6954562 0.413018382 0.779176 10.3641804 0.000758701 -10.3641804 
RNU44 22.542562 
 
22.510897 23.98059 23.759356 23.862974 23.3312758 0.660704987         
D425 mimic 
      
            
200b 26.116674 26.044378 26.088703 24.615269 24.326649 24.432652 25.27072083 0.817162275 0.827505 0.2459315 0.843271148 -0.074032758 
RNU48 25.216892 25.094225 25.117048 24.979593 24.903418 24.83756 25.02478933 0.130425547         
D425 control 
      
            
200b 34.248333 34.372295 34.1505 33.76569 34.66682 33.299202 34.08380667 0.441861531 0.493221 9.328851833 0.001555019 -9.328851833 
RNU48 24.608341 24.972895 24.366798 24.999498 24.735964 24.846233 24.75495483 0.219147201         
PER547 mimic 
      
            
200b 21.938042 22.042686 22.033072 25.474108 25.3925   23.3760816 1.680311545 1.720426 1.1938188 0.437144211 -1.1938188 
RNU44 22.827246 21.958355 21.736357 22.10297 22.286386 21.860746 22.1822628 0.369350512         
PER547 control 
      
            
200b 36.95305 37.725636 36.3772 35.42836 34.3852 35.96322 36.13877767 1.068375121 2.170457 12.18951917 0.000214086 -12.18951917 
RNU44 22.153275 22.079008 21.961515 25.992462 25.910704 25.598587 23.9492585 1.889301078         
D283 mimic 
      
            
200b 25.095387 25.30452 25.715897 25.835491 25.698816 25.5942 25.5407185 0.258051448 0.456851 1.740204833 0.299327175 -1.740204833 
RNU44 23.887083 24.141254 24.051447 22.99429 23.801323 23.927685 23.80051367 0.376991504         
D283 control 
      
            
200b 36.616478 0 36.453217 33.53491 32.781097 32.351334 34.3474072 2.042113168 2.230966 10.5703502 0.000657669 -10.5703502 
RNU44 22.72779 23.953176 22.627365 24.514252 24.520742 24.495136 23.777057 0.898322239         
 
 
 
 
 
 
 
 
qRT-PCR analysis of miR-200b expression in cell lines, 24 hours post-transfection with 50nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to RNU44/RNU48 
  1 1 1 2 2 2 Average SD Ct SD ΔCt 2^-ΔCt Log2 RQ 
D341 mimic                         
200b 21.70596 21.71921 21.4992 21.0093 21.00304 24.07897 21.83594667 1.045000335 1.540448 -0.46181 1.377268651 0.46181 
RNU44 21.30863 21.16586 21.03312 23.4757 23.43556 23.36767 22.29775667 1.131792751         
D341 control                         
200b 31.64931 31.72205 31.58662 31.64931 31.72205 31.58662 31.65266 0.055339787 0.087961 7.27798 0.00644332 -7.27798 
RNU44 24.47125 24.3222 24.33059 24.47125 24.3222 24.33059 24.37468 0.068371152         
D425 mimic                         
200b 25.96286 25.49348 25.42987 22.06564 21.67721 31.76428 25.286096 3.311787449 3.339333 -0.093160667 1.066704568 0.093160667 
RNU48 25.83469 25.7955 25.78981 24.95746 24.98006 24.91802 25.37925667 0.428026818         
D425 control                         
200b 32.17822 31.98237 31.8603 32.17822 31.98237 31.8603 32.00696333 0.130950132 0.138942 7.06575 0.007464441 -7.06575 
RNU48 24.97568 24.87556 24.9724 24.97568 24.87556 24.9724 24.94121333 0.046443225         
PER547 mimic                         
200b 21.48369 21.45464 21.48848 21.64073 21.45058 21.31722 21.47255667 0.094510347 0.537933 -1.36995 2.584616084 1.36995 
RNU44 22.37408 22.26259 22.3184 23.46352 23.40174 23.23471 22.84250667 0.529565485         
PER547 control                         
200b 32.83283 32.98308 33.08717 32.83283 32.98308 33.08717 32.96769333 0.104402334 0.125423 8.09478 0.003657871 -8.09478 
RNU44 24.96535 24.85565 24.79774 24.96535 24.85565 24.79774 24.87291333 0.06950681         
D283 mimic                         
200b 22.76589 22.880306 22.77436 21.13978 20.98208 21.03628 21.92978267 0.879059396 0.891459 -0.994464 1.99234018 0.994464 
RNU44 23.01532 23.09686 23.04672 22.93132 22.75279 22.70247 22.92424667 0.148167553         
D283 control                         
200b 32.44007 32.6546 32.32044 32.44007 32.6546 32.32044 32.47170333 0.138241883 0.147225 8.792446667 0.002255329 -8.792446667 
RNU44 23.73654 23.68784 23.61339 23.73654 23.68784 23.61339 23.67925667 0.050640799         
 
 
 
 
 
 
 
 
 
 
qRT-PCR analysis of DACH1 expression in cell lines, Log2 normalised to GAPDH, relative to D283 
  1 1 1 1 2 2 2 3 3 Average Ct Standard Deviation Ct SD ΔCt ΔΔCt 2^-ΔΔCt Log2 RQ 
Daoy 
                DACH1 32.94137 33.04392 33.36116 33.56143 35 35 
 
32.31932 32.52079 33.468499 0.960992 1.5634146 18.667709 9.8798465 0.0010614 -9.879846 
GAPDH 13.49108 13.79862 13.979 14.14775 16.819 16.853 
 
14.55992 14.75795 14.80079 1.2331908 
     UW228 
                DACH1 27.7054 27.8913 28.35166 28.48279 22.28466 27.26823 27.03695 29.44535 28.09034 27.395187 1.9260906 2.4187078 10.980673 2.1928111 0.2187248 -2.192811 
GAPDH 14.57776 14.75679 14.78471 15.13801 17.35307 17.8131 17.76897 18.27613 17.26208 16.414513 1.4629841 
     
PER547 
                DACH1 22.71583 22.69571 22.78952 22.88313 21.56316 21.38265 21.66921 19.97557 
 
21.959348 0.9464508 1.4715609 5.1282463 -3.659616 12.637297 3.659616 
GAPDH 15.87293 15.81801 15.89992 15.96786 18.2921 18.41454 18.11345 16.27 
 
16.831101 1.1268196 
     D283 
                DACH1 27.27899 27.72077 27.85543 27.92399 25.00596 24.94711 24.89661 25.77412 24.47594 26.208769 1.3758596 1.7212747 8.7878622 0 1 0 
GAPDH 16.45743 16.48814 16.53477 16.64414 18.21558 18.29747 18.98769 18.7073 16.45564 17.420907 1.0343099 
     D341 
                DACH1 23.22119 23.27677 23.29145 23.23901 25.99904 22.20039 
   
23.537975 1.1665269 1.2683836 6.9259158 -1.861946 3.6349774 1.8619464 
GAPDH 15.93585 16.08492 16.5373 16.69411 17.32265 17.097525 
   
16.612059 0.4980081 
     D425 
                DACH1 23.57904 23.52437 23.02143 23.00439 25.05538 24.94749 
   
23.85535 0.8404654 1.5976112 7.9584917 -0.829370 1.7769099 0.8293706 
GAPDH 15.46338 15.1391 14.7202 14.6054 18.25849 17.19458 
   
15.896858 1.3586682 
      
 
 
 
 
 
 
 
 
 
 
 
qRT-PCR analysis of DACH1 expression in cell lines, 24 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to GAPDH 
 
1 1 1 2 2 2 Average SD Ct SD ΔCt 2^ΔCt Log2 RQ 
D341 mimic             
DACH1 23.91269 23.88669 23.8998 24.35321 24.4582 24.71346 24.2040083 0.3226235 0.591888 5.98396033 63.29239841 5.983960333 
GAPDH 18.77639 18..81374 18.85933 17.68149 17.83187 17.95116 18.220048 0.4962309     
  
D425mimic                     
  
DACH1 28.29979 28.23658 28.35454 27.10415 27.33318 27.45576 27.7973333 0.51128814 0.880431 9.164265 573.7446557 9.164265 
GAPDH 19.59138 19.55558 19.09992 17.73256 17.83134 17.98763 18.6330683 0.80183266     
  
PER547 mimic                     
  
DACH1 23.73677 23.70025 23.74679 23.78208 23.87966 23.93569 23.7968733 0.08346592 0.175963 5.62017167 49.18585809 5.620171667 
GAPDH 18.35739 18.32396 18.35612 18.0478 17.99704 17.9779 18.1767017 0.17075337     
  
D283 mimic                     
  
DACH1 27.80856 27.76054 27.87219 27.3417 27.54622   27.665842 0.19559811 0.602938 9.620732 787.2794443 9.620732 
GAPDH 18.5109 18.55209 18.46779 17.34076 17.35401 17.3701 18.04511 0.57032895     
  
D341 control                     
  
DACH1 23.13936 23.17296 23.19764 26.62645 26.53385 26.42056 24.84847 1.67962377 1.558344 7.015495 129.3821696 7.015495 
GAPDH 17.75568 17.98409 17.99052 17.75189 17.73875 17.77692 17.832975 0.10971628     
  
D425 control                     
  
DACH1 27.90295 27.94307 27.7853 26.47859 26.44867 26.58408 27.1904433 0.68951752 0.898571 8.78111333 439.9248642 8.781113333 
GAPDH 19.05323 19.1196 19.09992 17.66661 17.71298 17.80364 18.40933 0.68305709     
  
PER547                     
  
DACH1  22.9135 22.91904 22.9501 23.61335 23.67364 23.62402 23.282275 0.3553969 0.7277777 5.54459167 46.67543836 5.544591667 
GAPDH 18.46054 18.40936 18.44321 17.07402 16.96351 17.07546 17.7376833 0.7011624     
  
D283 control                     
  
DACH1 27.55064 27.59835 27.561 27.86538 27.86538 27.93596 27.702266 0.1291298 0.454163 9.450232 699.5250931 9.450232 
GAPDH 18.58314 18.60515 
18.60237 17.68924 25.94112 17.78027 18.252034 0.39311391     
   
 
 
 
 
 
 
qRT-PCR analysis of DACH1 expression in cell lines, 48 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to GAPDH 
 
1 1 1 2 2 2 Average SD Ct SD ΔCt 2^ΔCt Log2 RQ 
D341 mimic             
DACH1 23.299927 23.431452 23.508732 24.93911 24.966257 24.952692 24.18302833 0.772107428 1.119886 4.71537483 26.27055607 4.715374833 
GAPDH 18.943432 18.579432 18.484972 20.317513 20.274754 20.205818 19.4676535 0.81116868         
D341 control 
      
            
DACH1 23.952806 23.958572 24.042336 23.884453 23.878902 23.847736 23.9274675 0.065025981 0.132252 4.89886767 29.83363091 4.898867667 
GAPDH 19.24158 18.916302 18.899393 19.045921 19.081867 18.986536 19.02859983 0.115161148         
D425mimic 
      
            
DACH1 26.06653 26.27913 26.442982 27.98095 27.969145 27.992262 27.12183317 27.12183317 1.111041 7.89874633 238.6489756 7.898746333 
GAPDH 18.508165 18.52896 18.544676 19.878576 19.944468 19.933676 19.22308683 19.22308683         
D425 control 
      
            
DACH1 25.4806 25.741081 25.930473 27.702425 27.660604 27.638617 26.6923 0.983776386 -1.153707 7.395872 168.4144363 7.395872 
GAPDH 18.817703 18.719215 18.566668 19.944006 19.958818 19.772158 19.296428 0.602679979         
PER547 mimic 
      
            
DACH1 22.879507 22.907139 22.927818 22.686193 22.721674 22.697565 22.803316 22.803316 0.541169 4.62042033 24.59716831 4.620420333 
GAPDH 17.54823 17.87284 17.635185 18.55324 18.996838 18.491041 18.18289567 18.18289567         
PER547 control 
      
            
DACH1  22.501484 22.606667 22.935978 23.2088 23.197466 23.114368 22.9274605 0.280305278 0.555234 4.64546233 25.02784785 4.645462333 
GAPDH 17.891216 17.81557 17.711107 18.742556 18.796707 18.734833 18.28199817 0.479284319         
D283 mimic 
      
            
DACH1 26.19131 26.163534 26.210775 27.599478 27.612772 27.557426 26.88921583 0.701008718 0.775911 8.18087533 290.1942922 8.180875333 
GAPDH 18.35787 18.43601 18.344559 19.11062 19.031214 18.96977 18.7083405 0.332603851         
D283 control 
      
            
DACH1 26.738604 26.66084 26.774017 27.350254 27.338509 27.33284 27.03251067 0.309874357 0.319274 8.71453267 420.0836037 8.714532667 
GAPDH 18.409344 18.323383 18.221207       18.317978 0.076901639         
 
 
 
 
 
 
 qRT-PCR analysis of DACH1 expression in cell lines, 24 hours post-transfection with 50nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to GAPDH 
 
1 1 1 2 2 2 Average SD Ct SD ΔCt 2^ΔCt Log2 RQ 
D341 mimic 
            
DACH1 23.17405 23.12604 22.91455 23.75813 23.58543 23.6579 23.36935 0.312326337 1.032196333 5.409946667 42.51637428 5.409946667 
GAPDH 17.06121 16.82255 17.05308 18.94008 18.97713 18.90237 17.95940333 0.983809702       
 
D341 control                       
 
DACH1 25.29235 25.63156 25.59295 25.29235 25.63156 25.59295 25.50562 0.151626191 0.155278891 6.102083333 68.69262606 6.102083333 
GAPDH 19.44129 19.40941 19.35991 19.44129 19.40941 19.35991 19.40353667 0.033481817       
 
D425mimic                       
 
DACH1 27.1276 27.08355 27.03174 28.37879 28.3133 28.36819 27.717195 0.637157805 0.707991419 8.36563 329.8417019 8.36563 
GAPDH 19.07971 19.09004 18.97393 19.72562 19.58329 19.6568 19.351565 0.30867747       
 
D425 control                       
 
DACH1 28.78645 28.58378 28.47351 28.78645 28.58378 28.47351 28.61458 0.12960026 0.153605192 9.209646667 592.0793251 9.209646667 
GAPDH 19.51728 19.3758 19.32172 19.51728 19.3758 19.32172 19.40493333 0.082451973       
 
PER547 mimic                       
 
DACH1 24.11801 24.12504 23.8416 23.21038 23.19758 23.17419 23.61113333 0.427529331 0.51569891 4.771745 27.31733803 4.771745 
GAPDH 18.67534 18.63002 18.39411 19.14321 19.14737 19.04628 18.83938833 0.288381756       
 
PER547 control                       
 
DACH1  25.51031 25.60321 25.27715 25.51031 25.60321 25.27715 25.46355667 0.137157298 0.156392311 5.149146667 35.4852279 5.149146667 
GAPDH 20.36198 20.37292 20.20833 20.36198 20.37292 20.20833 20.31441 0.075142734       
 
D283 mimic                       
 
DACH1 28.02566 27.97278 27.91611 27.92245 28.01564 27.60113 27.90896167 0.143796683 0.383694633 9.079776667 541.109465 9.079776667 
GAPDH 18.50107 18.52217 18.41807 19.29328 19.16208 19.07844 18.829185 0.355730355       
 
D283 control                       
 
DACH1 29.96095 29.90553 29.79715 29.96095 29.90553 29.79715 29.88787667 0.068026172 0.076160602 9.954003333 991.8673175 9.954003333 
GAPDH 19.96734 19.88682 19.94746 19.96734 19.88682 19.94746 19.93387333 0.034247294       
  
 
 
 
 
